CINXE.COM

<!DOCTYPE html> <html lang="en" xmlns:fb="http://www.facebook.com/2008/fbml" class="wf-loading"> <head prefix="og: https://ogp.me/ns# fb: https://ogp.me/ns/fb# academia: https://ogp.me/ns/fb/academia#"> <meta charset="utf-8"> <meta name=viewport content="width=device-width, initial-scale=1"> <meta rel="search" type="application/opensearchdescription+xml" href="/open_search.xml" title="Academia.edu"> <title>Jan Nyman - Academia.edu</title>  <link href="//a.academia-assets.com/images/favicons/favicon-production.ico" rel="shortcut icon" type="image/vnd.microsoft.icon"> <link rel="apple-touch-icon" sizes="57x57" href="//a.academia-assets.com/images/favicons/apple-touch-icon-57x57.png"> <link rel="apple-touch-icon" sizes="60x60" href="//a.academia-assets.com/images/favicons/apple-touch-icon-60x60.png"> <link rel="apple-touch-icon" sizes="72x72" href="//a.academia-assets.com/images/favicons/apple-touch-icon-72x72.png"> <link rel="apple-touch-icon" sizes="76x76" href="//a.academia-assets.com/images/favicons/apple-touch-icon-76x76.png"> <link rel="apple-touch-icon" sizes="114x114" href="//a.academia-assets.com/images/favicons/apple-touch-icon-114x114.png"> <link rel="apple-touch-icon" sizes="120x120" href="//a.academia-assets.com/images/favicons/apple-touch-icon-120x120.png"> <link rel="apple-touch-icon" sizes="144x144" href="//a.academia-assets.com/images/favicons/apple-touch-icon-144x144.png"> <link rel="apple-touch-icon" sizes="152x152" href="//a.academia-assets.com/images/favicons/apple-touch-icon-152x152.png"> <link rel="apple-touch-icon" sizes="180x180" href="//a.academia-assets.com/images/favicons/apple-touch-icon-180x180.png"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-32x32.png" sizes="32x32"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-194x194.png" sizes="194x194"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-96x96.png" sizes="96x96"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/android-chrome-192x192.png" sizes="192x192"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-16x16.png" sizes="16x16"> <link rel="manifest" href="//a.academia-assets.com/images/favicons/manifest.json"> <meta name="msapplication-TileColor" content="#2b5797"> <meta name="msapplication-TileImage" content="//a.academia-assets.com/images/favicons/mstile-144x144.png"> <meta name="theme-color" content="#ffffff"> <script> window.performance && window.performance.measure && window.performance.measure("Time To First Byte", "requestStart", "responseStart"); </script> <script> (function() { if (!window.URLSearchParams || !window.history || !window.history.replaceState) { return; } var searchParams = new URLSearchParams(window.location.search); var paramsToDelete = [ 'fs', 'sm', 'swp', 'iid', 'nbs', 'rcc', // related content category 'rcpos', // related content carousel position 'rcpg', // related carousel page 'rchid', // related content hit id 'f_ri', // research interest id, for SEO tracking 'f_fri', // featured research interest, for SEO tracking (param key without value) 'f_rid', // from research interest directory for SEO tracking 'f_loswp', // from research interest pills on LOSWP sidebar for SEO tracking 'rhid', // referrring hit id ]; if (paramsToDelete.every((key) => searchParams.get(key) === null)) { return; } paramsToDelete.forEach((key) => { searchParams.delete(key); }); var cleanUrl = new URL(window.location.href); cleanUrl.search = searchParams.toString(); history.replaceState({}, document.title, cleanUrl); })(); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-5VKX33P2DS"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5VKX33P2DS', { cookie_domain: 'academia.edu', send_page_view: false, }); gtag('event', 'page_view', { 'controller': "profiles/works", 'action': "summary", 'controller_action': 'profiles/works#summary', 'logged_in': 'false', 'edge': 'unknown', // Send nil if there is no A/B test bucket, in case some records get logged // with missing data - that way we can distinguish between the two cases. // ab_test_bucket should be of the form <ab_test_name>:<bucket> 'ab_test_bucket': null, }) </script> <script type="text/javascript"> window.sendUserTiming = function(timingName) { if (!(window.performance && window.performance.measure)) return; var entries = window.performance.getEntriesByName(timingName, "measure"); if (entries.length !== 1) return; var timingValue = Math.round(entries[0].duration); gtag('event', 'timing_complete', { name: timingName, value: timingValue, event_category: 'User-centric', }); }; window.sendUserTiming("Time To First Byte"); </script> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="C5ly3RzWMlWzkqhoc4h6KItNfzGcFrE+a3mHvciIGXcYXmbyDvivuEeOgvLcwVV3ahJfZ872c6DMlkT/xaevXQ==" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/wow-77f7b87cb1583fc59aa8f94756ebfe913345937eb932042b4077563bebb5fb4b.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/social/home-9e8218e1301001388038e3fc3427ed00d079a4760ff7745d1ec1b2d59103170a.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/heading-b2b823dd904da60a48fd1bfa1defd840610c2ff414d3f39ed3af46277ab8df3b.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/button-3cea6e0ad4715ed965c49bfb15dedfc632787b32ff6d8c3a474182b231146ab7.css" /><link crossorigin="" href="https://fonts.gstatic.com/" rel="preconnect" /><link href="https://fonts.googleapis.com/css2?family=DM+Sans:ital,opsz,wght@0,9..40,100..1000;1,9..40,100..1000&family=Gupter:wght@400;500;700&family=IBM+Plex+Mono:wght@300;400&family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20,400,0,0&display=swap" rel="stylesheet" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/common-10fa40af19d25203774df2d4a03b9b5771b45109c2304968038e88a81d1215c5.css" /> <meta name="author" content="jan nyman" /> <meta name="description" content="Jan Nyman: 2 Followers, 4 Following, 128 Research papers. Research interests: Radiation Therapy, Lung Cancer, and European." /> <meta name="google-site-verification" content="bKJMBZA7E43xhDOopFZkssMMkBRjvYERV-NaN4R6mrs" /> <script> var $controller_name = 'works'; var $action_name = "summary"; var $rails_env = 'production'; var $app_rev = '9387f500ddcbb8d05c67bef28a2fe0334f1aafb8'; var $domain = 'academia.edu'; var $app_host = "academia.edu"; var $asset_host = "academia-assets.com"; var $start_time = new Date().getTime(); var $recaptcha_key = "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB"; var $recaptcha_invisible_key = "6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj"; var $disableClientRecordHit = false; </script> <script> window.Aedu = { hit_data: null }; window.Aedu.SiteStats = {"premium_universities_count":15267,"monthly_visitors":"113 million","monthly_visitor_count":113692424,"monthly_visitor_count_in_millions":113,"user_count":277738666,"paper_count":55203019,"paper_count_in_millions":55,"page_count":432000000,"page_count_in_millions":432,"pdf_count":16500000,"pdf_count_in_millions":16}; window.Aedu.serverRenderTime = new Date(1733047580000); window.Aedu.timeDifference = new Date().getTime() - 1733047580000; window.Aedu.isUsingCssV1 = false; window.Aedu.enableLocalization = true; window.Aedu.activateFullstory = false; window.Aedu.serviceAvailability = { status: {"attention_db":"on","bibliography_db":"on","contacts_db":"on","email_db":"on","indexability_db":"on","mentions_db":"on","news_db":"on","notifications_db":"on","offsite_mentions_db":"on","redshift":"on","redshift_exports_db":"on","related_works_db":"on","ring_db":"on","user_tests_db":"on"}, serviceEnabled: function(service) { return this.status[service] === "on"; }, readEnabled: function(service) { return this.serviceEnabled(service) || this.status[service] === "read_only"; }, }; window.Aedu.viewApmTrace = function() { // Check if x-apm-trace-id meta tag is set, and open the trace in APM // in a new window if it is. var apmTraceId = document.head.querySelector('meta[name="x-apm-trace-id"]'); if (apmTraceId) { var traceId = apmTraceId.content; // Use trace ID to construct URL, an example URL looks like: // https://app.datadoghq.com/apm/traces?query=trace_id%31298410148923562634 var apmUrl = 'https://app.datadoghq.com/apm/traces?query=trace_id%3A' + traceId; window.open(apmUrl, '_blank'); } }; </script>  <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet"> <link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet"> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/libraries-a9675dcb01ec4ef6aa807ba772c7a5a00c1820d3ff661c1038a20f80d06bb4e4.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/academia-bdb9e8c097f01e611f2fc5e2f1a9dc599beede975e2ae5629983543a1726e947.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system_legacy-056a9113b9a0f5343d013b29ee1929d5a18be35fdcdceb616600b4db8bd20054.css" /> <script src="//a.academia-assets.com/assets/webpack_bundles/runtime-bundle-005434038af4252ca37c527588411a3d6a0eabb5f727fac83f8bbe7fd88d93bb.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/webpack_libraries_and_infrequently_changed.wjs-bundle-3e572e3b706c3ed2ec5b2c1cb44a411fadc81f62a97963cb7bd9c327a0a9d5f2.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/core_webpack.wjs-bundle-2e8d3f30eaaddd1debd6ce4630b3453b23a23c91ac7c823ddf8822879835b029.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/sentry.wjs-bundle-5fe03fddca915c8ba0f7edbe64c194308e8ce5abaed7bffe1255ff37549c4808.js"></script> <script> jade = window.jade || {}; jade.helpers = window.$h; jade._ = window._; </script>  <script id="tag-manager-head-root">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer_old','GTM-5G9JF7Z');</script>  <script> window.gptadslots = []; window.googletag = window.googletag || {}; window.googletag.cmd = window.googletag.cmd || []; </script> <script type="text/javascript"> // TODO(jacob): This should be defined, may be rare load order problem. // Checking if null is just a quick fix, will default to en if unset. // Better fix is to run this immedietely after I18n is set. if (window.I18n != null) { I18n.defaultLocale = "en"; I18n.locale = "en"; I18n.fallbacks = true; } </script> <link rel="canonical" href="https://independent.academia.edu/JanNyman" /> </head>   <body class='c-profiles/works a-summary logged_out'>  <div id="fb-root"></div><script>window.fbAsyncInit = function() { FB.init({ appId: "2369844204", version: "v8.0", status: true, cookie: true, xfbml: true }); // Additional initialization code. if (window.InitFacebook) { // facebook.ts already loaded, set it up. window.InitFacebook(); } else { // Set a flag for facebook.ts to find when it loads. window.academiaAuthReadyFacebook = true; } };</script><script>window.fbAsyncLoad = function() { // Protection against double calling of this function if (window.FB) { return; } (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk')); } if (!window.defer_facebook) { // Autoload if not deferred window.fbAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.fbAsyncLoad(); }, 5000); }</script> <div id="google-root"></div><script>window.loadGoogle = function() { if (window.InitGoogle) { // google.ts already loaded, set it up. window.InitGoogle("331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"); } else { // Set a flag for google.ts to use when it loads. window.GoogleClientID = "331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"; } };</script><script>window.googleAsyncLoad = function() { // Protection against double calling of this function (function(d) { var js; var id = 'google-jssdk'; var ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) { return; } js = d.createElement('script'); js.id = id; js.async = true; js.onload = loadGoogle; js.src = "https://accounts.google.com/gsi/client" ref.parentNode.insertBefore(js, ref); }(document)); } if (!window.defer_google) { // Autoload if not deferred window.googleAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.googleAsyncLoad(); }, 5000); }</script> <div id="tag-manager-body-root">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5G9JF7Z" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script> window.addEventListener('load', function() { if (document.querySelector('input[name="commit"]')) { document.querySelector('input[name="commit"]').addEventListener('click', function() { gtag('event', 'click', { event_category: 'button', event_label: 'Log In' }) }) } }); </script> </div> <script>var _comscore = _comscore || []; _comscore.push({ c1: "2", c2: "26766707" }); (function() { var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true; s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js"; el.parentNode.insertBefore(s, el); })();</script><img src="https://sb.scorecardresearch.com/p?c1=2&c2=26766707&cv=2.0&cj=1" style="position: absolute; visibility: hidden" /> <div id='react-modal'></div> <div class='DesignSystem'> <a class='u-showOnFocus' href='#site'> Skip to main content </a> </div> <div id="upgrade_ie_banner" style="display: none;"><p>Academia.edu no longer supports Internet Explorer.</p><p>To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to <a href="https://www.academia.edu/upgrade-browser">upgrade your browser</a>.</p></div><script>// Show this banner for all versions of IE if (!!window.MSInputMethodContext || /(MSIE)/.test(navigator.userAgent)) { document.getElementById('upgrade_ie_banner').style.display = 'block'; }</script> <div class="DesignSystem bootstrap ShrinkableNav"><div class="navbar navbar-default main-header"><div class="container-wrapper" id="main-header-container"><div class="container"><div class="navbar-header"><div class="nav-left-wrapper u-mt0x"><div class="nav-logo"><a data-main-header-link-target="logo_home" href="https://www.academia.edu/"><img class="visible-xs-inline-block" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015-A.svg" width="24" height="24" /><img width="145.2" height="18" class="hidden-xs" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015.svg" /></a></div><div class="nav-search"><div class="SiteSearch-wrapper select2-no-default-pills"><form class="js-SiteSearch-form DesignSystem" action="https://www.academia.edu/search" accept-charset="UTF-8" method="get"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><i class="SiteSearch-icon fa fa-search u-fw700 u-positionAbsolute u-tcGrayDark"></i><input class="js-SiteSearch-form-input SiteSearch-form-input form-control" data-main-header-click-target="search_input" name="q" placeholder="Search" type="text" value="" /></form></div></div></div><div class="nav-right-wrapper pull-right"><ul class="NavLinks js-main-nav list-unstyled"><li class="NavLinks-link"><a class="js-header-login-url Button Button--inverseGray Button--sm u-mb4x" id="nav_log_in" rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="NavLinks-link u-p0x"><a class="Button Button--inverseGray Button--sm u-mb4x" rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li></ul><button class="hidden-lg hidden-md hidden-sm u-ml4x navbar-toggle collapsed" data-target=".js-mobile-header-links" data-toggle="collapse" type="button"><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button></div></div><div class="collapse navbar-collapse js-mobile-header-links"><ul class="nav navbar-nav"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li><li class="u-borderColorGrayLight u-borderBottom1 js-mobile-nav-expand-trigger"><a href="#">more&nbsp<span class="caret"></span></a></li><li><ul class="js-mobile-nav-expand-section nav navbar-nav u-m0x collapse"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/about">About</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/press">Press</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://medium.com/@academia">Blog</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/documents">Papers</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/hiring"><i class="fa fa-briefcase"></i> We're Hiring!</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://support.academia.edu/"><i class="fa fa-question-circle"></i> Help Center</a></li><li class="js-mobile-nav-collapse-trigger u-borderColorGrayLight u-borderBottom1 dropup" style="display:none"><a href="#">less&nbsp<span class="caret"></span></a></li></ul></li></ul></div></div></div><script>(function(){ var $moreLink = $(".js-mobile-nav-expand-trigger"); var $lessLink = $(".js-mobile-nav-collapse-trigger"); var $section = $('.js-mobile-nav-expand-section'); $moreLink.click(function(ev){ ev.preventDefault(); $moreLink.hide(); $lessLink.show(); $section.collapse('show'); }); $lessLink.click(function(ev){ ev.preventDefault(); $moreLink.show(); $lessLink.hide(); $section.collapse('hide'); }); })() if ($a.is_logged_in() || false) { new Aedu.NavigationController({ el: '.js-main-nav', showHighlightedNotification: false }); } else { $(".js-header-login-url").attr("href", $a.loginUrlWithRedirect()); } Aedu.autocompleteSearch = new AutocompleteSearch({el: '.js-SiteSearch-form'});</script></div></div> <div id='site' class='fixed'> <div id="content" class="clearfix"> <script>document.addEventListener('DOMContentLoaded', function(){ var $dismissible = $(".dismissible_banner"); $dismissible.click(function(ev) { $dismissible.hide(); }); });</script> <script src="//a.academia-assets.com/assets/webpack_bundles/profile.wjs-bundle-ae3d0ee232cd83d11499343688b0160a3c7db15e95cb2d0844cae78d49ea53f1.js" defer="defer"></script><script>Aedu.rankings = { showPaperRankingsLink: false } $viewedUser = Aedu.User.set_viewed( {"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman","photo":"/images/s65_no_pic.png","has_photo":false,"is_analytics_public":false,"interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":279027,"name":"European","url":"https://www.academia.edu/Documents/in/European"},{"id":100966,"name":"Brain Plasticity","url":"https://www.academia.edu/Documents/in/Brain_Plasticity"},{"id":1432374,"name":"Facultad De Ciencias Políticas Y Sociales","url":"https://www.academia.edu/Documents/in/Facultad_De_Ciencias_Pol%C3%ADticas_Y_Sociales"}]} ); if ($a.is_logged_in() && $viewedUser.is_current_user()) { $('body').addClass('profile-viewed-by-owner'); } $socialProfiles = []</script><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://independent.academia.edu/JanNyman","location":"/JanNyman","scheme":"https","host":"independent.academia.edu","port":null,"pathname":"/JanNyman","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="ProfileCheckPaperUpdate" data-props="{}" data-trace="false" data-dom-id="ProfileCheckPaperUpdate-react-component-c57af22c-bb55-4a63-a7ed-48c7d8a1a593"></div> <div id="ProfileCheckPaperUpdate-react-component-c57af22c-bb55-4a63-a7ed-48c7d8a1a593"></div> <div class="DesignSystem"><div class="onsite-ping" id="onsite-ping"></div></div><div class="profile-user-info DesignSystem"><div class="social-profile-container"><div class="left-panel-container"><div class="user-info-component-wrapper"><div class="user-summary-cta-container"><div class="user-summary-container"><div class="social-profile-avatar-container"><img class="profile-avatar u-positionAbsolute" border="0" alt="" src="//a.academia-assets.com/images/s200_no_pic.png" /></div><div class="title-container"><h1 class="ds2-5-heading-sans-serif-sm">Jan Nyman</h1><div class="affiliations-container fake-truncate js-profile-affiliations"></div></div></div><div class="sidebar-cta-container"><button class="ds2-5-button hidden profile-cta-button grow js-profile-follow-button" data-broccoli-component="user-info.follow-button" data-click-track="profile-user-info-follow-button" data-follow-user-fname="Jan" data-follow-user-id="39973590" data-follow-user-source="profile_button" data-has-google="false"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">add</span>Follow</button><button class="ds2-5-button hidden profile-cta-button grow js-profile-unfollow-button" data-broccoli-component="user-info.unfollow-button" data-click-track="profile-user-info-unfollow-button" data-unfollow-user-id="39973590"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">done</span>Following</button></div></div><div class="user-stats-container"><a><div class="stat-container js-profile-followers"><p class="label">Followers</p><p class="data">2</p></div></a><a><div class="stat-container js-profile-followees" data-broccoli-component="user-info.followees-count" data-click-track="profile-expand-user-info-following"><p class="label">Following</p><p class="data">4</p></div></a><a><div class="stat-container js-profile-coauthors" data-broccoli-component="user-info.coauthors-count" data-click-track="profile-expand-user-info-coauthors"><p class="label">Co-authors</p><p class="data">2</p></div></a><a href="/JanNyman/mentions"><div class="stat-container"><p class="label">Mentions</p><p class="data">1</p></div></a><span><div class="stat-container"><p class="label"><span class="js-profile-total-view-text">Public Views</span></p><p class="data"><span class="js-profile-view-count"></span></p></div></span></div><div class="ri-section"><div class="ri-section-header"><span>Interests</span></div><div class="ri-tags-container"><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="39973590" href="https://www.academia.edu/Documents/in/Radiation_Therapy"><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://independent.academia.edu/JanNyman","location":"/JanNyman","scheme":"https","host":"independent.academia.edu","port":null,"pathname":"/JanNyman","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation Therapy"]}" data-trace="false" data-dom-id="Pill-react-component-ce900b13-0d98-4a94-ab5d-767aaff9a6e0"></div> <div id="Pill-react-component-ce900b13-0d98-4a94-ab5d-767aaff9a6e0"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="39973590" href="https://www.academia.edu/Documents/in/Lung_Cancer"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Lung Cancer"]}" data-trace="false" data-dom-id="Pill-react-component-bc5cf67a-b52f-49a8-a4a5-4e9c77c9f444"></div> <div id="Pill-react-component-bc5cf67a-b52f-49a8-a4a5-4e9c77c9f444"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="39973590" href="https://www.academia.edu/Documents/in/European"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["European"]}" data-trace="false" data-dom-id="Pill-react-component-f69f6b85-4f1d-49d8-8863-cf3b5f9307b0"></div> <div id="Pill-react-component-f69f6b85-4f1d-49d8-8863-cf3b5f9307b0"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="39973590" href="https://www.academia.edu/Documents/in/Brain_Plasticity"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Brain Plasticity"]}" data-trace="false" data-dom-id="Pill-react-component-18b209ab-836f-4dfe-bba1-74a1bb0ae158"></div> <div id="Pill-react-component-18b209ab-836f-4dfe-bba1-74a1bb0ae158"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="39973590" href="https://www.academia.edu/Documents/in/Facultad_De_Ciencias_Pol%C3%ADticas_Y_Sociales"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Facultad De Ciencias Políticas Y Sociales"]}" data-trace="false" data-dom-id="Pill-react-component-256813fc-644e-45aa-b913-3af143c55f1e"></div> <div id="Pill-react-component-256813fc-644e-45aa-b913-3af143c55f1e"></div> </a></div></div></div></div><div class="right-panel-container"><div class="user-content-wrapper"><div class="uploads-container" id="social-redesign-work-container"><div class="upload-header"><h2 class="ds2-5-heading-sans-serif-xs">Uploads</h2></div><div class="documents-container backbone-social-profile-documents" style="width: 100%;"><div class="u-taCenter"></div><div class="profile--tab_content_container js-tab-pane tab-pane active" id="all"><div class="profile--tab_heading_container js-section-heading" data-section="Papers" id="Papers"><h3 class="profile--tab_heading_container">Papers by Jan Nyman</h3></div><div class="js-work-strip profile--work_container" data-work-id="125124512"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival"><img alt="Research paper thumbnail of Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival" class="work-thumbnail" src="https://attachments.academia-assets.com/119223677/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival">Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival</a></div><div class="wp-workCard_item"><span>International Archives of Otorhinolaryngology</span><span>, Sep 30, 2020</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d1d8520cf413381182105944dd41cecc" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":119223677,"asset_id":125124512,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="125124512"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="125124512"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 125124512; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=125124512]").text(description); $(".js-view-count[data-work-id=125124512]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 125124512; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='125124512']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 125124512, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d1d8520cf413381182105944dd41cecc" } } $('.js-work-strip[data-work-id=125124512]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":125124512,"title":"Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival","translated_title":"","metadata":{"publisher":"Thieme Revinter Publicações","grobid_abstract":"Introduction Head and neck cancer of unknown primary (HNCUP) is a rare condition whose prognostic factors that are significant for survival vary between studies. No randomized treatment study has been performed thus far, and the optimal treatment is not established. Objective The present study aimed to explore various prognostic factors and compare the two main treatments for HNCUP: neck dissection and (chemo) radiation vs primary (chemo) radiation. Methods A national multicenter study was performed with data from the Swedish Head and Neck Cancer Register (SweHNCR) and from the patients' medical records from 2008 to 2012. Results Two-hundred and sixty HNCUP patients were included. The tumors were HPVpositive in 80%. The overall 5-year survival rate of patients treated with curative intent was 71%. Age (p \u003c 0.001), performance status (p¼ 0.036), and N stage (p¼ 0.046) were significant factors for overall survival according to the multivariable analysis. Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups. Conclusions Age, performance status, and N stage were significant prognostic factors. Treatment with neck dissection and (chemo) radiation and primary (chemo) radiation gave similar survival outcomes. A randomized treatment study that includes quality of life is needed to establish the optimal treatment.","publication_date":{"day":30,"month":9,"year":2020,"errors":{}},"publication_name":"International Archives of Otorhinolaryngology","grobid_abstract_attachment_id":119223677},"translated_abstract":null,"internal_url":"https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival","translated_internal_url":"","created_at":"2024-10-28T22:28:07.181-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":119223677,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223677/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223677/s-0040-1712106-libre.pdf?1730181885=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=Jrx16dgcOQ3PXavQYUmlP126TqzzCOo~m1tqGtUqptkNYNzLgrO6sm8vWwLCIb2AB2j9yCncBxr9ucG2RP3VReOUTegoR~mLZlwcby0c86wk0Ai1Ul0pKTYBwOqVeoVTwWGo97-scql39l7khK-2E~QYksLxJtu6Pp7ORUtSIkzz9ZlIovFFEHgzk3VCmfRqpl6bRS0jlqOnhcWXS6sDEoT2pGbqd~49xAyLjtzpFjdoSaAFH~KifrzDmJuDLZCZuCFnZCOC-HDtAZRHO8SKqMpLMTfClRz-2xai8t7NfbtO9ykVTeTDhGLQI-ok8qu0CQeChc96Z7yTivdYZtokdw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":119223677,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223677/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223677/s-0040-1712106-libre.pdf?1730181885=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=Jrx16dgcOQ3PXavQYUmlP126TqzzCOo~m1tqGtUqptkNYNzLgrO6sm8vWwLCIb2AB2j9yCncBxr9ucG2RP3VReOUTegoR~mLZlwcby0c86wk0Ai1Ul0pKTYBwOqVeoVTwWGo97-scql39l7khK-2E~QYksLxJtu6Pp7ORUtSIkzz9ZlIovFFEHgzk3VCmfRqpl6bRS0jlqOnhcWXS6sDEoT2pGbqd~49xAyLjtzpFjdoSaAFH~KifrzDmJuDLZCZuCFnZCOC-HDtAZRHO8SKqMpLMTfClRz-2xai8t7NfbtO9ykVTeTDhGLQI-ok8qu0CQeChc96Z7yTivdYZtokdw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":119223676,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223676/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223676/download_file","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223676/s-0040-1712106-libre.pdf?1730181886=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=gK~QwMZVb2MxHrq33-sunFLDZKBRInMd8qD72JKR3GRcl-3UOpLxdsysBh4dAiYbyUNWzELlMRtBp4uVbT-hCj3qeif2RbbdC5lwfw2xcSqHYSrnAfIqXEk00Bweflf~q6-Xdce4kvHHK~dUfUwS6L04a3OWd9kghRVVT0QMcH6gUjkb-owCwgQLqpyaeZF6GCIfcwzTOl6M0xa2n~HahV0OU71aaNjH-Di46DyMBXWQGXS3EGd28b1tSN8fslLF-mGnj0iTrQRNylfwFKj2fyv8XXAHnlk160-AG8w-IXkl8nyWKWcpR3lmgxOc7aE8pxjCaWYf6JzzDEzQy9nMMQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":647,"name":"Surgery","url":"https://www.academia.edu/Documents/in/Surgery"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":53661,"name":"Head and Neck","url":"https://www.academia.edu/Documents/in/Head_and_Neck"},{"id":98549,"name":"Head and Neck Cancer","url":"https://www.academia.edu/Documents/in/Head_and_Neck_Cancer"},{"id":1225372,"name":"Overall Survival","url":"https://www.academia.edu/Documents/in/Overall_Survival"},{"id":3194190,"name":"Neck dissection","url":"https://www.academia.edu/Documents/in/Neck_dissection"}],"urls":[{"id":45376750,"url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1712106.pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504849"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy"><img alt="Research paper thumbnail of Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy">Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy</a></div><div class="wp-workCard_item"><span>PubMed</span><span>, Oct 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation p...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504849"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504849"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504849; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504849]").text(description); $(".js-view-count[data-work-id=114504849]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504849; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504849']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504849, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504849]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504849,"title":"Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy","translated_title":"","metadata":{"abstract":"Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.","publication_date":{"day":1,"month":10,"year":2015,"errors":{}},"publication_name":"PubMed"},"translated_abstract":"Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.","internal_url":"https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:09.592-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":98939,"name":"Pubmed","url":"https://www.academia.edu/Documents/in/Pubmed"},{"id":189574,"name":"Mucositis","url":"https://www.academia.edu/Documents/in/Mucositis"},{"id":263843,"name":"Anticancer","url":"https://www.academia.edu/Documents/in/Anticancer"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1745478,"name":"Adenocarcinoma","url":"https://www.academia.edu/Documents/in/Adenocarcinoma"},{"id":1971418,"name":"Esophagitis","url":"https://www.academia.edu/Documents/in/Esophagitis"},{"id":2464960,"name":"Pneumonitis","url":"https://www.academia.edu/Documents/in/Pneumonitis"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206135,"url":"https://pubmed.ncbi.nlm.nih.gov/26408714"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504848"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy"><img alt="Research paper thumbnail of The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186095/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy">The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy</a></div><div class="wp-workCard_item"><span>PubMed</span><span>, Apr 1, 2012</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Aim: The aim of the present study was to retrospectively investigate the impact of induction chem...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="cd782d58f508ffd8ea0a056c0648a5d1" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186095,"asset_id":114504848,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504848"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504848"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504848; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504848]").text(description); $(".js-view-count[data-work-id=114504848]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504848; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504848']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504848, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "cd782d58f508ffd8ea0a056c0648a5d1" } } $('.js-work-strip[data-work-id=114504848]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504848,"title":"The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy","translated_title":"","metadata":{"abstract":"Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.","publication_date":{"day":1,"month":4,"year":2012,"errors":{}},"publication_name":"PubMed"},"translated_abstract":"Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.","internal_url":"https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:09.300-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186095,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186095/thumbnails/1.jpg","file_name":"1339.full.pdf","download_url":"https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_induction_chemotherapy_for.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186095/1339.full-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_induction_chemotherapy_for.pdf\u0026Expires=1733027654\u0026Signature=Dg-E8xnITFXbHaIr7SGXR8mtOgUPVuhdYPq~Ney~ICfi0x0AXIXnWVs9oxu9DG~QE5WO5auDl6SQo5X4l6-V~GhLlH2Ke2J4adnf4GYRDAm3RXdnp03Yg~Btn5hU2bqvdAT8zB6GbbjLQV4e4Roo6KJDbOLlzJbmPt~FlTziWwoPfUJyPEZ8oPIxjVo4imCtR1KPMejZJVrAffdn2SVRnLu8voFxc9dbcJPHwzQ2pE8X9ABSigk3qrkmT4U4xajM3rQTQ2GmivNnFgC~mquPT8TRwb5JCWv~9ODmDuWfuc3CjddRxQw5RZDmtHFVYkTko3lPnGZW5xSj3ftgIlJYOw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy","translated_slug":"","page_count":8,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186095,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186095/thumbnails/1.jpg","file_name":"1339.full.pdf","download_url":"https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_induction_chemotherapy_for.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186095/1339.full-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_induction_chemotherapy_for.pdf\u0026Expires=1733027654\u0026Signature=Dg-E8xnITFXbHaIr7SGXR8mtOgUPVuhdYPq~Ney~ICfi0x0AXIXnWVs9oxu9DG~QE5WO5auDl6SQo5X4l6-V~GhLlH2Ke2J4adnf4GYRDAm3RXdnp03Yg~Btn5hU2bqvdAT8zB6GbbjLQV4e4Roo6KJDbOLlzJbmPt~FlTziWwoPfUJyPEZ8oPIxjVo4imCtR1KPMejZJVrAffdn2SVRnLu8voFxc9dbcJPHwzQ2pE8X9ABSigk3qrkmT4U4xajM3rQTQ2GmivNnFgC~mquPT8TRwb5JCWv~9ODmDuWfuc3CjddRxQw5RZDmtHFVYkTko3lPnGZW5xSj3ftgIlJYOw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":10610,"name":"Survival Analysis","url":"https://www.academia.edu/Documents/in/Survival_Analysis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":66080,"name":"Age","url":"https://www.academia.edu/Documents/in/Age"},{"id":98939,"name":"Pubmed","url":"https://www.academia.edu/Documents/in/Pubmed"},{"id":263843,"name":"Anticancer","url":"https://www.academia.edu/Documents/in/Anticancer"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1281465,"name":"Univariate Analysis","url":"https://www.academia.edu/Documents/in/Univariate_Analysis"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"},{"id":4320322,"name":"hazard ratio","url":"https://www.academia.edu/Documents/in/hazard_ratio"}],"urls":[{"id":39206134,"url":"https://pubmed.ncbi.nlm.nih.gov/22493368"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504846"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186130/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer">Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>European Journal of Cancer</span><span>, Nov 1, 2011</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="61cdc8d2abb71efdc2d1c2a6ddc130df" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186130,"asset_id":114504846,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504846"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504846"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504846; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504846]").text(description); $(".js-view-count[data-work-id=114504846]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504846; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504846']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504846, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "61cdc8d2abb71efdc2d1c2a6ddc130df" } } $('.js-work-strip[data-work-id=114504846]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504846,"title":"Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"j o u r n a l h o m e p a g e : w w w. e j c o n l i n e. c o m after curatively intended radiation therapy in comparison with squamous cell carcinoma patients, particularly those with clinical stages IIA-IIB.","publication_date":{"day":1,"month":11,"year":2011,"errors":{}},"publication_name":"European Journal of Cancer","grobid_abstract_attachment_id":111186130},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:08.220-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186130,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186130/thumbnails/1.jpg","file_name":"j.ejca.2011.06.01120240205-1-229v36.pdf","download_url":"https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_Lung_Cancer_Radiation_Study_Grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186130/j.ejca.2011.06.01120240205-1-229v36-libre.pdf?1707145115=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_Lung_Cancer_Radiation_Study_Grou.pdf\u0026Expires=1733051180\u0026Signature=RDXXqk4F95ULUz1j-un6PFaqUYqlHKUPWEsoL-kPZGId3too47VwO1x2u3wO3IgkFc9tuiP~dsYbrx~ang6RNEbRzOG1rIw0MFHaqpwtVQv~uyfurttdT2paXJ4zbpd3DKeFsV3Z-5asY-UvWjJc9hUJjKE0F1pmCkyHdNDFSOHksOYhPmlU5enVCYv6TOtL1YOt3Vjc0t5ywmjEeJqYpNhRB7ki1-yWD15y1JjHG6o0AS9FoSPurd6RIRlxJ2LX0w8vVOp1Tf9xOsHuGQ5O8JCG8K0RJbEsCSaSe9mXeOpUQ7Z1Y-~Bm-7SfC4W7YGsI6hZgbFF-criHc29Aj4juA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186130,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186130/thumbnails/1.jpg","file_name":"j.ejca.2011.06.01120240205-1-229v36.pdf","download_url":"https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_Lung_Cancer_Radiation_Study_Grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186130/j.ejca.2011.06.01120240205-1-229v36-libre.pdf?1707145115=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_Lung_Cancer_Radiation_Study_Grou.pdf\u0026Expires=1733051180\u0026Signature=RDXXqk4F95ULUz1j-un6PFaqUYqlHKUPWEsoL-kPZGId3too47VwO1x2u3wO3IgkFc9tuiP~dsYbrx~ang6RNEbRzOG1rIw0MFHaqpwtVQv~uyfurttdT2paXJ4zbpd3DKeFsV3Z-5asY-UvWjJc9hUJjKE0F1pmCkyHdNDFSOHksOYhPmlU5enVCYv6TOtL1YOt3Vjc0t5ywmjEeJqYpNhRB7ki1-yWD15y1JjHG6o0AS9FoSPurd6RIRlxJ2LX0w8vVOp1Tf9xOsHuGQ5O8JCG8K0RJbEsCSaSe9mXeOpUQ7Z1Y-~Bm-7SfC4W7YGsI6hZgbFF-criHc29Aj4juA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":12069,"name":"Histology","url":"https://www.academia.edu/Documents/in/Histology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":212690,"name":"Non small cell carcinoma","url":"https://www.academia.edu/Documents/in/Non_small_cell_carcinoma"},{"id":279027,"name":"European","url":"https://www.academia.edu/Documents/in/European"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":410532,"name":"Clinical Data","url":"https://www.academia.edu/Documents/in/Clinical_Data"},{"id":1225372,"name":"Overall Survival","url":"https://www.academia.edu/Documents/in/Overall_Survival"},{"id":1548118,"name":"Non small Cell Lung Cancer","url":"https://www.academia.edu/Documents/in/Non_small_Cell_Lung_Cancer"},{"id":1745478,"name":"Adenocarcinoma","url":"https://www.academia.edu/Documents/in/Adenocarcinoma"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206132,"url":"https://doi.org/10.1016/j.ejca.2011.06.011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504845"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC"><img alt="Research paper thumbnail of How to improve loco-regional control in stages IIIa–b NSCLC?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC">How to improve loco-regional control in stages IIIa–b NSCLC?</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Jul 1, 2009</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-sma...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS&amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504845"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504845"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504845; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504845]").text(description); $(".js-view-count[data-work-id=114504845]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504845; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504845']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504845, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504845]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504845,"title":"How to improve loco-regional control in stages IIIa–b NSCLC?","translated_title":"","metadata":{"abstract":"A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS\u0026amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.","publisher":"Elsevier BV","publication_date":{"day":1,"month":7,"year":2009,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":"A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS\u0026amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.","internal_url":"https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC","translated_internal_url":"","created_at":"2024-02-05T05:55:07.850-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":7523,"name":"Control","url":"https://www.academia.edu/Documents/in/Control"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":97056,"name":"Clinical Medicine","url":"https://www.academia.edu/Documents/in/Clinical_Medicine"},{"id":128538,"name":"Arm","url":"https://www.academia.edu/Documents/in/Arm"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1548118,"name":"Non small Cell Lung Cancer","url":"https://www.academia.edu/Documents/in/Non_small_Cell_Lung_Cancer"},{"id":1938454,"name":"Adverse effects","url":"https://www.academia.edu/Documents/in/Adverse_effects"},{"id":2007840,"name":"Carboplatin","url":"https://www.academia.edu/Documents/in/Carboplatin"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206131,"url":"https://doi.org/10.1016/j.lungcan.2008.10.021"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504844"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group">Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Feb 1, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Several attempts to increase the locoregional control in locally advanced lung cancer including c...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1&amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss&amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504844"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504844"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504844; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504844]").text(description); $(".js-view-count[data-work-id=114504844]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504844; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504844']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504844, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504844]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504844,"title":"Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"abstract":"Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1\u0026amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss\u0026amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.","publisher":"Elsevier BV","publication_date":{"day":1,"month":2,"year":2011,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":"Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1\u0026amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss\u0026amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.","internal_url":"https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:07.603-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":53661,"name":"Head and Neck","url":"https://www.academia.edu/Documents/in/Head_and_Neck"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":276781,"name":"Cisplatin","url":"https://www.academia.edu/Documents/in/Cisplatin"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1128165,"name":"EGF receptor","url":"https://www.academia.edu/Documents/in/EGF_receptor"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2326675,"name":"Docetaxel","url":"https://www.academia.edu/Documents/in/Docetaxel"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3703401,"name":"Locally advanced","url":"https://www.academia.edu/Documents/in/Locally_advanced"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206130,"url":"https://doi.org/10.1016/j.lungcan.2010.05.011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504843"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials"><img alt="Research paper thumbnail of Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials" class="work-thumbnail" src="https://attachments.academia-assets.com/111186120/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials">Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, Jul 1, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c17f6d5d01463d606906c2c58acac0a0" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186120,"asset_id":114504843,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504843"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504843"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504843; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504843]").text(description); $(".js-view-count[data-work-id=114504843]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504843; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504843']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504843, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c17f6d5d01463d606906c2c58acac0a0" } } $('.js-work-strip[data-work-id=114504843]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504843,"title":"Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Physical/role functioning improved 6 months after concurrent chemoradiation (CCRT)/radiation (RT) + radical surgery (RS). • Tumor-related symptoms of fatigue and insomnia decreased 6 months after treatment. • Treatment-related symptoms of lymphedema and menopausal symptoms increased after treatment. • Sexuality was not impaired significantly except for a worsened sexual worry in the RT + RS group. • Generally RT + RS seems superior to CCRT+RS with greater improvement in functioning and less toxicity.","publication_date":{"day":1,"month":7,"year":2012,"errors":{}},"publication_name":"Radiotherapy and Oncology","grobid_abstract_attachment_id":111186120},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials","translated_internal_url":"","created_at":"2024-02-05T05:55:07.338-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186120,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186120/thumbnails/1.jpg","file_name":"j.ygyno.2019.07.00520240205-1-tud1hw.pdf","download_url":"https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Health_related_quality_of_life_in_locall.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186120/j.ygyno.2019.07.00520240205-1-tud1hw-libre.pdf?1707145120=\u0026response-content-disposition=attachment%3B+filename%3DHealth_related_quality_of_life_in_locall.pdf\u0026Expires=1733051180\u0026Signature=Irk40IyXmZRAAy55xdeyqVaLP5SKhZr9uP7~sxfhVutBHZuO~Jhwjj9JzXfCZhk3Gw-Y2HO71z~2dP3~48xJKgggJgF2vnk2XeTtaoEbXttFE-UyllIirebhyLiuv3JogcN5CWTh6OVEVugtZm8om17E1l-hGhPrctboj8sm1bjit2nCCuhwMP7-x5T~IYdAGXf79dScXfFIMvLYtOdSoZLLnSdoTZNeJUhIBScN1kOtoqQY6gLAGijFqxnfqZYzrrJz2JMuvUjrT39ODmzYUBFhmU~HS452gIU4ViSNIfXwwaefMCbeybgs4ZFln2kV0PAGaUdcgYXsAR89ARYsPQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186120,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186120/thumbnails/1.jpg","file_name":"j.ygyno.2019.07.00520240205-1-tud1hw.pdf","download_url":"https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Health_related_quality_of_life_in_locall.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186120/j.ygyno.2019.07.00520240205-1-tud1hw-libre.pdf?1707145120=\u0026response-content-disposition=attachment%3B+filename%3DHealth_related_quality_of_life_in_locall.pdf\u0026Expires=1733051180\u0026Signature=Irk40IyXmZRAAy55xdeyqVaLP5SKhZr9uP7~sxfhVutBHZuO~Jhwjj9JzXfCZhk3Gw-Y2HO71z~2dP3~48xJKgggJgF2vnk2XeTtaoEbXttFE-UyllIirebhyLiuv3JogcN5CWTh6OVEVugtZm8om17E1l-hGhPrctboj8sm1bjit2nCCuhwMP7-x5T~IYdAGXf79dScXfFIMvLYtOdSoZLLnSdoTZNeJUhIBScN1kOtoqQY6gLAGijFqxnfqZYzrrJz2JMuvUjrT39ODmzYUBFhmU~HS452gIU4ViSNIfXwwaefMCbeybgs4ZFln2kV0PAGaUdcgYXsAR89ARYsPQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":62112,"name":"Prospective studies","url":"https://www.academia.edu/Documents/in/Prospective_studies"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":147196,"name":"Monoclonal Antibodies","url":"https://www.academia.edu/Documents/in/Monoclonal_Antibodies"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2463778,"name":"Clinical Trials as Topic","url":"https://www.academia.edu/Documents/in/Clinical_Trials_as_Topic"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206129,"url":"https://doi.org/10.1016/j.radonc.2012.05.006"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504842"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group">Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, 2009</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504842"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504842"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504842; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504842]").text(description); $(".js-view-count[data-work-id=114504842]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504842; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504842']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504842, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504842]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504842,"title":"Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2009,"errors":{}},"publication_name":"Journal of Thoracic Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:07.091-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":276781,"name":"Cisplatin","url":"https://www.academia.edu/Documents/in/Cisplatin"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2326675,"name":"Docetaxel","url":"https://www.academia.edu/Documents/in/Docetaxel"}],"urls":[{"id":39206128,"url":"https://lup.lub.lu.se/search/publication/c99afce8-9ad1-4bc9-94cd-dc9e6822d10b"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504841"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://attachments.academia-assets.com/111186083/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group">PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, Aug 1, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="2b0ad3aed07e251711d0a7cef7639404" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186083,"asset_id":114504841,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504841"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504841"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504841; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504841]").text(description); $(".js-view-count[data-work-id=114504841]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504841; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504841']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504841, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "2b0ad3aed07e251711d0a7cef7639404" } } $('.js-work-strip[data-work-id=114504841]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504841,"title":"PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Background: Induction chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to","publication_date":{"day":1,"month":8,"year":2007,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":111186083},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:06.807-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186083,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186083/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"PD4_1_3_How_to_improve_loco_regional_con.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186083/pdf-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPD4_1_3_How_to_improve_loco_regional_con.pdf\u0026Expires=1733027655\u0026Signature=DtVHa9sHxnHh8OVyn5d~eLWFMqaLkDzZFs-qvpGYdgpZq2Gmc~oOCe6JzD6xZqt96vlfvKEqUVKcWO6989RqIDuR3Fz3CI65LHGRkF9-TcEjMsHF~y2dJ9NuUhK0VoarP9KihHmxdw0FImuOkcff~ZFeiqnfS4eI2z0bpbMojOKivo2ZxvkbLphZB2YflpcdnUXrbNL6juqA5e8IO6Ia4~fanixOQlcwIf0UnAepRtEYWQkinVnVh1n79j~tWH12lagp~kLfLFZjTQ5HbcLQ59ZI6chmUSLzGZIWxR3V7lONtnCbxGRnY9Q2ZDmAnr~28qeygf9YY~0xwdPRRWj-jQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186083,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186083/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"PD4_1_3_How_to_improve_loco_regional_con.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186083/pdf-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPD4_1_3_How_to_improve_loco_regional_con.pdf\u0026Expires=1733027655\u0026Signature=DtVHa9sHxnHh8OVyn5d~eLWFMqaLkDzZFs-qvpGYdgpZq2Gmc~oOCe6JzD6xZqt96vlfvKEqUVKcWO6989RqIDuR3Fz3CI65LHGRkF9-TcEjMsHF~y2dJ9NuUhK0VoarP9KihHmxdw0FImuOkcff~ZFeiqnfS4eI2z0bpbMojOKivo2ZxvkbLphZB2YflpcdnUXrbNL6juqA5e8IO6Ia4~fanixOQlcwIf0UnAepRtEYWQkinVnVh1n79j~tWH12lagp~kLfLFZjTQ5HbcLQ59ZI6chmUSLzGZIWxR3V7lONtnCbxGRnY9Q2ZDmAnr~28qeygf9YY~0xwdPRRWj-jQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":203752,"name":"Randomized Trial","url":"https://www.academia.edu/Documents/in/Randomized_Trial"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":413196,"name":"Randomized Controlled Trial","url":"https://www.academia.edu/Documents/in/Randomized_Controlled_Trial"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":39206127,"url":"https://doi.org/10.1097/01.jto.0000283373.63338.99"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504840"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_"><img alt="Research paper thumbnail of P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_">P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Jul 1, 2005</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504840"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504840"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504840; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504840]").text(description); $(".js-view-count[data-work-id=114504840]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504840; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504840']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504840, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504840]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504840,"title":"P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":7,"year":2005,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_","translated_internal_url":"","created_at":"2024-02-05T05:55:06.427-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":99773,"name":"Disease","url":"https://www.academia.edu/Documents/in/Disease"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"}],"urls":[{"id":39206126,"url":"https://doi.org/10.1016/s0169-5002(05)81260-7"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504839"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186085/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer">The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>Medical Oncology</span><span>, Dec 18, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d60d2ad65180401d664dfc306650381a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186085,"asset_id":114504839,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504839"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504839"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504839; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504839]").text(description); $(".js-view-count[data-work-id=114504839]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504839; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504839']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504839, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d60d2ad65180401d664dfc306650381a" } } $('.js-work-strip[data-work-id=114504839]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504839,"title":"The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Springer Science+Business Media","grobid_abstract":"The prognosis for patients with lung cancer is poor with an average of 5-year overall survival rate of only 10-15 % taking all clinical stages together. The aim of this study was to elucidate the impact of the radiotherapy regimen on survival. Clinical data were collected from all the Swedish Oncology Departments for 1,287 patients with a diagnosed non-small cell lung cancer (NSCLC) subjected to curatively intended irradiation (C50 Gy) during the years 1990 to 2000. The included patients were identified based on a manual search of all medical and radiation charts at the oncology departments from which the individual patient data were collected. Patients who did not have a histopathological diagnosis date and/or death date/ last follow-up date as well as patients being surgically treated were excluded from the study (n = 592). Thus, 695","publication_date":{"day":18,"month":12,"year":2012,"errors":{}},"publication_name":"Medical Oncology","grobid_abstract_attachment_id":111186085},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:05.979-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186085,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186085/thumbnails/1.jpg","file_name":"s12032-012-0320-y20240205-1-au4b5x.pdf","download_url":"https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_impact_of_hyperfractionated_radiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186085/s12032-012-0320-y20240205-1-au4b5x-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DThe_impact_of_hyperfractionated_radiothe.pdf\u0026Expires=1733027655\u0026Signature=UqgzqWikdWl7zjLhCFZveu0Si5fLAr7IzaL7B4d9k4JCO2U0zh1dv5VIf~-OzOlT0dJTxHLQ9kuj7Nw9dzRodo1i9EyRGFgD~1imjKbl-UcS0gCjd0U7P1lt8i9hb0e8O~RmPg6lR29zg3BkhTeyHhoqeSWav~gHGHPxkAzSCwTNP~Y9jAC3Ukghd1AVNNJaFMWycoWhbNYoSBhdD84xSTL3l9uXOj2CBbXvK~iYbislWno60V9rUJfelMn42X5NMETX-IWT7l0ZJo6Vf5sr~Y1nt~C6uH2UP3lRRwyxR9AHZwSahQf3SqcihxBAUnuuzDoUIX4jQ4XmLhoSX88pxQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186085,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186085/thumbnails/1.jpg","file_name":"s12032-012-0320-y20240205-1-au4b5x.pdf","download_url":"https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_impact_of_hyperfractionated_radiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186085/s12032-012-0320-y20240205-1-au4b5x-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DThe_impact_of_hyperfractionated_radiothe.pdf\u0026Expires=1733027655\u0026Signature=UqgzqWikdWl7zjLhCFZveu0Si5fLAr7IzaL7B4d9k4JCO2U0zh1dv5VIf~-OzOlT0dJTxHLQ9kuj7Nw9dzRodo1i9EyRGFgD~1imjKbl-UcS0gCjd0U7P1lt8i9hb0e8O~RmPg6lR29zg3BkhTeyHhoqeSWav~gHGHPxkAzSCwTNP~Y9jAC3Ukghd1AVNNJaFMWycoWhbNYoSBhdD84xSTL3l9uXOj2CBbXvK~iYbislWno60V9rUJfelMn42X5NMETX-IWT7l0ZJo6Vf5sr~Y1nt~C6uH2UP3lRRwyxR9AHZwSahQf3SqcihxBAUnuuzDoUIX4jQ4XmLhoSX88pxQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":4531,"name":"Clinical Trial","url":"https://www.academia.edu/Documents/in/Clinical_Trial"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":64900,"name":"Medical Oncology","url":"https://www.academia.edu/Documents/in/Medical_Oncology"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1034951,"name":"Regimen","url":"https://www.academia.edu/Documents/in/Regimen"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"},{"id":1740333,"name":"Hyperfractionation","url":"https://www.academia.edu/Documents/in/Hyperfractionation"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206125,"url":"https://doi.org/10.1007/s12032-012-0320-y"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504838"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply"><img alt="Research paper thumbnail of Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply">Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply</a></div><div class="wp-workCard_item"><span>Lancet Oncology</span><span>, Jun 1, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504838"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504838"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504838; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504838]").text(description); $(".js-view-count[data-work-id=114504838]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504838; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504838']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504838, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504838]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504838,"title":"Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":6,"year":2021,"errors":{}},"publication_name":"Lancet Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply","translated_internal_url":"","created_at":"2024-02-05T05:55:05.677-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":243630,"name":"Lancet Oncology","url":"https://www.academia.edu/Documents/in/Lancet_Oncology"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"}],"urls":[{"id":39206124,"url":"https://doi.org/10.1016/s1470-2045(21)00291-6"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504837"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer"><img alt="Research paper thumbnail of OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186092/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer">OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, Apr 1, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="249bdab42652a70f05acd773b670c172" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186092,"asset_id":114504837,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504837"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504837"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504837; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504837]").text(description); $(".js-view-count[data-work-id=114504837]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504837; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504837']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504837, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "249bdab42652a70f05acd773b670c172" } } $('.js-work-strip[data-work-id=114504837]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504837,"title":"OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Using median C20 to stratify the patient data resulted in two significantly different survival distributions when all calcifications were used (p=0.003, log-rank test) but borderline for calcifications only in the heart. Figure 2 shows the corresponding Kaplan-Meier survival estimates. Conclusion Our results suggest that the risk of death increases by 27% for every extra cm 3 of calcifications receiving at least 20 Gy. Moreover, the loss of significance when analysing data to only the calcifications within the heart suggest an important dose/effect relation for calcifications outside the heart and these should not be ignored. We are planning to validate of our findings in an external cohort. OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer","publication_date":{"day":1,"month":4,"year":2019,"errors":{}},"publication_name":"Radiotherapy and Oncology","grobid_abstract_attachment_id":111186092},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:05.433-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186092,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186092/thumbnails/1.jpg","file_name":"s0167-814028192930825-420240205-1-54058o.pdf","download_url":"https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"OC_0405_Registry_based_modelling_of_earl.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186092/s0167-814028192930825-420240205-1-54058o-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DOC_0405_Registry_based_modelling_of_earl.pdf\u0026Expires=1733027655\u0026Signature=UMAYxhPA3g86ud~YSu5HXSvlz3m~y9YZOICHmlYoB-sOD112Gr0JeaGw3R4ej8l0YL1dfmU0aPohEOmEP4rJMBWAqWnlP5z1Zn4qFz-M22ba937aOSobIKgN~SaWZlNzkCNc0r9TzfL3879lIBFAbKDlsBszJFwiI3xvPdhpqrmJoP~dqeT4iyywZcRX45IBVAdN8NN6S--P52mghVzeHjrsn69Mdg-IF0hXST7TCRgV80PeTHTgauuUQmqTlaW60yEqmlFvLNZ04KFha-dOEStWqIAnZcufV2dkKiQIEZcqR2X6~cPYScDjy~mqaXEkrb4V3A9lZfq48LJ0Krav9g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer","translated_slug":"","page_count":2,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186092,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186092/thumbnails/1.jpg","file_name":"s0167-814028192930825-420240205-1-54058o.pdf","download_url":"https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"OC_0405_Registry_based_modelling_of_earl.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186092/s0167-814028192930825-420240205-1-54058o-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DOC_0405_Registry_based_modelling_of_earl.pdf\u0026Expires=1733027655\u0026Signature=UMAYxhPA3g86ud~YSu5HXSvlz3m~y9YZOICHmlYoB-sOD112Gr0JeaGw3R4ej8l0YL1dfmU0aPohEOmEP4rJMBWAqWnlP5z1Zn4qFz-M22ba937aOSobIKgN~SaWZlNzkCNc0r9TzfL3879lIBFAbKDlsBszJFwiI3xvPdhpqrmJoP~dqeT4iyywZcRX45IBVAdN8NN6S--P52mghVzeHjrsn69Mdg-IF0hXST7TCRgV80PeTHTgauuUQmqTlaW60yEqmlFvLNZ04KFha-dOEStWqIAnZcufV2dkKiQIEZcqR2X6~cPYScDjy~mqaXEkrb4V3A9lZfq48LJ0Krav9g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":3676351,"name":"Radiotherapy and Oncology","url":"https://www.academia.edu/Documents/in/Radiotherapy_and_Oncology"}],"urls":[{"id":39206123,"url":"https://doi.org/10.1016/s0167-8140(19)30825-4"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504836"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_"><img alt="Research paper thumbnail of Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_">Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504836"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504836"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504836; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504836]").text(description); $(".js-view-count[data-work-id=114504836]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504836; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504836']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504836, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504836]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504836,"title":"Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)","translated_title":"","metadata":{"abstract":"8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...","publisher":"American Society of Clinical Oncology (ASCO)","publication_name":"Journal of Clinical Oncology"},"translated_abstract":"8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...","internal_url":"https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_","translated_internal_url":"","created_at":"2024-02-05T05:55:05.165-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":10035,"name":"Nuclear medicine","url":"https://www.academia.edu/Documents/in/Nuclear_medicine"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":115895,"name":"Clinical oncology","url":"https://www.academia.edu/Documents/in/Clinical_oncology"},{"id":413196,"name":"Randomized Controlled Trial","url":"https://www.academia.edu/Documents/in/Randomized_Controlled_Trial"},{"id":2180163,"name":"Prophylactic Cranial Irradiation","url":"https://www.academia.edu/Documents/in/Prophylactic_Cranial_Irradiation"},{"id":2484597,"name":"Etoposide","url":"https://www.academia.edu/Documents/in/Etoposide"}],"urls":[{"id":39206122,"url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2023.41.16_suppl.8512"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504835"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy"><img alt="Research paper thumbnail of The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186102/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy">The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="777993275d9a560079b10d7c38cb1324" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186102,"asset_id":114504835,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504835"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504835"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504835; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504835]").text(description); $(".js-view-count[data-work-id=114504835]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504835; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504835']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504835, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "777993275d9a560079b10d7c38cb1324" } } $('.js-work-strip[data-work-id=114504835]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504835,"title":"The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":111186102},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:04.915-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186102,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186102/thumbnails/1.jpg","file_name":"PIIS1556086421020748.pdf","download_url":"https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_HILUS_Trial_a_Prospective_Nordic_Mul.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186102/PIIS1556086421020748-libre.pdf?1707145127=\u0026response-content-disposition=attachment%3B+filename%3DThe_HILUS_Trial_a_Prospective_Nordic_Mul.pdf\u0026Expires=1733027655\u0026Signature=GfsCURbMxPLRjIpGlerQUOqVPtZXN8knzNHJb0WGg-J-J-oboPjVEl14NI1SZJB2olfR5DT1B7SW~LlRqlSmDpcwrNIU1n0c~JN9x54wq6Puh0iJmvPvwzDpVfn5A~iMC8CcH2YxOR1u98qIbikJzZb-IzwjjT4uNHX5XxA6rSeIusz7fSXXY0vveLzBvgrQcVs7joES3L1jIWQ-FihjfbJYDFL1-derDux~p0WqBjTOQqrNejnY2YZsamfvnXEctEcS6m4R4~U06sepId7AyzFvgfcowufDF~0vnfEczKRI6lSeZQ021axOX097Dd~pp5NUFcLyp4zACD0F22jlSQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy","translated_slug":"","page_count":12,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186102,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186102/thumbnails/1.jpg","file_name":"PIIS1556086421020748.pdf","download_url":"https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_HILUS_Trial_a_Prospective_Nordic_Mul.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186102/PIIS1556086421020748-libre.pdf?1707145127=\u0026response-content-disposition=attachment%3B+filename%3DThe_HILUS_Trial_a_Prospective_Nordic_Mul.pdf\u0026Expires=1733027655\u0026Signature=GfsCURbMxPLRjIpGlerQUOqVPtZXN8knzNHJb0WGg-J-J-oboPjVEl14NI1SZJB2olfR5DT1B7SW~LlRqlSmDpcwrNIU1n0c~JN9x54wq6Puh0iJmvPvwzDpVfn5A~iMC8CcH2YxOR1u98qIbikJzZb-IzwjjT4uNHX5XxA6rSeIusz7fSXXY0vveLzBvgrQcVs7joES3L1jIWQ-FihjfbJYDFL1-derDux~p0WqBjTOQqrNejnY2YZsamfvnXEctEcS6m4R4~U06sepId7AyzFvgfcowufDF~0vnfEczKRI6lSeZQ021axOX097Dd~pp5NUFcLyp4zACD0F22jlSQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":197297,"name":"Lung","url":"https://www.academia.edu/Documents/in/Lung"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":1281465,"name":"Univariate Analysis","url":"https://www.academia.edu/Documents/in/Univariate_Analysis"},{"id":2464960,"name":"Pneumonitis","url":"https://www.academia.edu/Documents/in/Pneumonitis"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":39206121,"url":"https://api.elsevier.com/content/article/PII:S1556086421020748?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504834"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy"><img alt="Research paper thumbnail of The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186086/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy">The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy</a></div><div class="wp-workCard_item"><span>Neoplasma</span><span>, 2017</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bfcfc7d4d6dbc8cc12e1519c1303dddd" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186086,"asset_id":114504834,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504834"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504834"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504834; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504834]").text(description); $(".js-view-count[data-work-id=114504834]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504834; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504834']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504834, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bfcfc7d4d6dbc8cc12e1519c1303dddd" } } $('.js-work-strip[data-work-id=114504834]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504834,"title":"The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy","translated_title":"","metadata":{"publisher":"AEPress, s.r.o.","grobid_abstract":"Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical data and the serum values of hemoglobin (Hgb), White blood cells (WBC) and Platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox proportional hazards regression model. The results showed that patients with thrombocytosis (Plt \u003e 350 x 10 9 /L) had a shorter median overall survival (14.5 months) than patients with normal Plt at baseline (23.7 months). Patients with leukocytosis (WBC \u003e 9 x 10 9 /L) had a shorter median survival (14.9 months) than patients with a normal WBC at baseline (22.5 months). However, in a multivariate model including all lab parameters and clinical factors, only thrombocytosis and performance status displayed a prognostic significance. In Conclusion, thrombocytosis showed to be an independent prognostic marker associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. This knowledge can potentially be used together with established prognostic factors, such as performance status when choosing the optimal therapy for the individual patient in this clinical setting.","publication_date":{"day":null,"month":null,"year":2017,"errors":{}},"publication_name":"Neoplasma","grobid_abstract_attachment_id":111186086},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:04.700-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186086,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186086/thumbnails/1.jpg","file_name":"90383ee698ff3d04cc931a876a64742e6fbb.pdf","download_url":"https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_prognostic_value_of_pre_treatment_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186086/90383ee698ff3d04cc931a876a64742e6fbb-libre.pdf?1707145126=\u0026response-content-disposition=attachment%3B+filename%3DThe_prognostic_value_of_pre_treatment_th.pdf\u0026Expires=1733027655\u0026Signature=WNebByLbVLoulvj8GJlbEn82uutLqKUMuglhnzkx47q1kI8yiYKdcfNUWA6nEQ9TsQH4PA73twtZ7Nc54NQVOHgDEhpqDgZ2xNk1jHRZccmpHZItz2bHxY4vDsGbt3QocyGSHLbSV7WIeT7DE068KE9RM-pk9kjcFmCSdq-MOQka1fmixNsQRZi0TIqoNFUOcE4wqgGxyXzPC9EprMge0oq4-DVlNfNcEDRGTElV0JAWoica23fcm9OV~wOyUyX8Gkn4plS0kUJ6HbK28V3XUHNiZg7ayBtv4ybXMi7xedUrGm8jurddXjHTPl5qCxXQJvXb2FT7oMW-o0exxGh3pQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186086,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186086/thumbnails/1.jpg","file_name":"90383ee698ff3d04cc931a876a64742e6fbb.pdf","download_url":"https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_prognostic_value_of_pre_treatment_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186086/90383ee698ff3d04cc931a876a64742e6fbb-libre.pdf?1707145126=\u0026response-content-disposition=attachment%3B+filename%3DThe_prognostic_value_of_pre_treatment_th.pdf\u0026Expires=1733027655\u0026Signature=WNebByLbVLoulvj8GJlbEn82uutLqKUMuglhnzkx47q1kI8yiYKdcfNUWA6nEQ9TsQH4PA73twtZ7Nc54NQVOHgDEhpqDgZ2xNk1jHRZccmpHZItz2bHxY4vDsGbt3QocyGSHLbSV7WIeT7DE068KE9RM-pk9kjcFmCSdq-MOQka1fmixNsQRZi0TIqoNFUOcE4wqgGxyXzPC9EprMge0oq4-DVlNfNcEDRGTElV0JAWoica23fcm9OV~wOyUyX8Gkn4plS0kUJ6HbK28V3XUHNiZg7ayBtv4ybXMi7xedUrGm8jurddXjHTPl5qCxXQJvXb2FT7oMW-o0exxGh3pQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":3274,"name":"Gastroenterology","url":"https://www.academia.edu/Documents/in/Gastroenterology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":418283,"name":"Proportional hazards model","url":"https://www.academia.edu/Documents/in/Proportional_hazards_model"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":1344434,"name":"Neoplasma","url":"https://www.academia.edu/Documents/in/Neoplasma"},{"id":3397707,"name":"Thrombocytosis","url":"https://www.academia.edu/Documents/in/Thrombocytosis"},{"id":3834133,"name":"leukocytosis","url":"https://www.academia.edu/Documents/in/leukocytosis"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504833"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study"><img alt="Research paper thumbnail of Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study" class="work-thumbnail" src="https://attachments.academia-assets.com/111186124/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study">Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study</a></div><div class="wp-workCard_item"><span>The Journal of Rheumatology</span><span>, 2013</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration &gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d0944487d04cb6f70a7896b46add6d2a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186124,"asset_id":114504833,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504833"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504833"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504833; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504833]").text(description); $(".js-view-count[data-work-id=114504833]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504833; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504833']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504833, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d0944487d04cb6f70a7896b46add6d2a" } } $('.js-work-strip[data-work-id=114504833]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504833,"title":"Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study","translated_title":"","metadata":{"abstract":"Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration \u0026gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...","publisher":"The Journal of Rheumatology","publication_date":{"day":null,"month":null,"year":2013,"errors":{}},"publication_name":"The Journal of Rheumatology"},"translated_abstract":"Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration \u0026gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...","internal_url":"https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study","translated_internal_url":"","created_at":"2024-02-05T05:55:03.466-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186124,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186124/thumbnails/1.jpg","file_name":"1158.full.pdf","download_url":"https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Patient_reported_Health_related_Quality.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186124/1158.full-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPatient_reported_Health_related_Quality.pdf\u0026Expires=1733051180\u0026Signature=D~70v5nEi3qw6hwoJR7roPYN9LnZeeFJGISmKnB4Zpd7TXO24XS5BTeyw2M1J8BFypEYWT0LXommrZdZxLf3g27Kg9Aj4RoUby~Nyjn3bJT65jmX2BSvPugPiM0SLTNjD7FXdHGae3VVG2fsDAM21OFbOpxfSsFjYPLa9oSSrcD9RTD1YhGXrq5ec5KiFUqrNY0eWGIHSc2~Pl7ysup-6nH72tHXEAxTeXZkmJU8IwfouKdcmEXUQs83DqaCHg-OtI4oC-qIfOXYrgiW8bHbQoMPhERL3C3wfQxtrEuuY5fPEnpez5rx3OlUm7Off3YQS0rIrlR3mbGvdWMdTQQ68g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study","translated_slug":"","page_count":8,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186124,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186124/thumbnails/1.jpg","file_name":"1158.full.pdf","download_url":"https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Patient_reported_Health_related_Quality.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186124/1158.full-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPatient_reported_Health_related_Quality.pdf\u0026Expires=1733051180\u0026Signature=D~70v5nEi3qw6hwoJR7roPYN9LnZeeFJGISmKnB4Zpd7TXO24XS5BTeyw2M1J8BFypEYWT0LXommrZdZxLf3g27Kg9Aj4RoUby~Nyjn3bJT65jmX2BSvPugPiM0SLTNjD7FXdHGae3VVG2fsDAM21OFbOpxfSsFjYPLa9oSSrcD9RTD1YhGXrq5ec5KiFUqrNY0eWGIHSc2~Pl7ysup-6nH72tHXEAxTeXZkmJU8IwfouKdcmEXUQs83DqaCHg-OtI4oC-qIfOXYrgiW8bHbQoMPhERL3C3wfQxtrEuuY5fPEnpez5rx3OlUm7Off3YQS0rIrlR3mbGvdWMdTQQ68g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1290,"name":"Immunology","url":"https://www.academia.edu/Documents/in/Immunology"},{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":23076,"name":"Fatigue","url":"https://www.academia.edu/Documents/in/Fatigue"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":32473,"name":"Physical Therapy","url":"https://www.academia.edu/Documents/in/Physical_Therapy"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":72938,"name":"Placebo","url":"https://www.academia.edu/Documents/in/Placebo"},{"id":144052,"name":"Patient Satisfaction","url":"https://www.academia.edu/Documents/in/Patient_Satisfaction"},{"id":205431,"name":"Psoriatic Arthritis","url":"https://www.academia.edu/Documents/in/Psoriatic_Arthritis"},{"id":232534,"name":"Health Status","url":"https://www.academia.edu/Documents/in/Health_Status"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":1262481,"name":"Pain Measurement","url":"https://www.academia.edu/Documents/in/Pain_Measurement"},{"id":2225268,"name":"Apremilast","url":"https://www.academia.edu/Documents/in/Apremilast"},{"id":2474752,"name":"Disability Evaluation","url":"https://www.academia.edu/Documents/in/Disability_Evaluation"}],"urls":[{"id":39206120,"url":"https://syndication.highwire.org/content/doi/10.3899/jrheum.121200"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504784"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186080/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer">Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>Medical Oncology</span><span>, May 8, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="eceee44affcbe1151c2cc3192ca3eec4" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186080,"asset_id":114504784,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504784"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504784"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504784; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504784]").text(description); $(".js-view-count[data-work-id=114504784]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504784; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504784']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504784, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "eceee44affcbe1151c2cc3192ca3eec4" } } $('.js-work-strip[data-work-id=114504784]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504784,"title":"Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Springer Science+Business Media","grobid_abstract":"There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention ([50 Gy), were included in the study. WBC, Plt,","publication_date":{"day":8,"month":5,"year":2012,"errors":{}},"publication_name":"Medical Oncology","grobid_abstract_attachment_id":111186080},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:53:14.172-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186080,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186080/thumbnails/1.jpg","file_name":"s12032-012-0247-320240205-1-alhlwl.pdf","download_url":"https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_lung_cancer_radiation_study_grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186080/s12032-012-0247-320240205-1-alhlwl-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_lung_cancer_radiation_study_grou.pdf\u0026Expires=1733027655\u0026Signature=GQK4sYvTIVJ19sCQgehsrSFFGsbJkeHSMs2KVjgBmM-9IGsz2IeAyOh86Um~Zx1lDugaLtxJDHuIGr2vrAixxn3ekd0ydZZei7Ng8TqNwoMXzmTkxIJXOaG8hs0UdlN2LWAylkqf16e01wR27lXVOiSxSsGCo0dPssivnGRhK-yizkEyAaQ~gw~i26MjJ3dUm4w7WEkdyCkIJhY8BST8SC56nqHn~o7VvGOmTpHgBHxyNoSBoBHpZTLoSMkfg1dIVCsbDA8t~0jZUjoGWKTRzT2SECP8mHRr45jYmaQmxagM0ERdChR4FOM1H6UKn5Ix87jdmHwZGFHWXPM2GZ22lw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186080,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186080/thumbnails/1.jpg","file_name":"s12032-012-0247-320240205-1-alhlwl.pdf","download_url":"https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_lung_cancer_radiation_study_grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186080/s12032-012-0247-320240205-1-alhlwl-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_lung_cancer_radiation_study_grou.pdf\u0026Expires=1733027655\u0026Signature=GQK4sYvTIVJ19sCQgehsrSFFGsbJkeHSMs2KVjgBmM-9IGsz2IeAyOh86Um~Zx1lDugaLtxJDHuIGr2vrAixxn3ekd0ydZZei7Ng8TqNwoMXzmTkxIJXOaG8hs0UdlN2LWAylkqf16e01wR27lXVOiSxSsGCo0dPssivnGRhK-yizkEyAaQ~gw~i26MjJ3dUm4w7WEkdyCkIJhY8BST8SC56nqHn~o7VvGOmTpHgBHxyNoSBoBHpZTLoSMkfg1dIVCsbDA8t~0jZUjoGWKTRzT2SECP8mHRr45jYmaQmxagM0ERdChR4FOM1H6UKn5Ix87jdmHwZGFHWXPM2GZ22lw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":619,"name":"Hematology","url":"https://www.academia.edu/Documents/in/Hematology"},{"id":3274,"name":"Gastroenterology","url":"https://www.academia.edu/Documents/in/Gastroenterology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":64900,"name":"Medical Oncology","url":"https://www.academia.edu/Documents/in/Medical_Oncology"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":136346,"name":"Anemia","url":"https://www.academia.edu/Documents/in/Anemia"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":338534,"name":"Biomarker","url":"https://www.academia.edu/Documents/in/Biomarker"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3834133,"name":"leukocytosis","url":"https://www.academia.edu/Documents/in/leukocytosis"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206096,"url":"https://doi.org/10.1007/s12032-012-0247-3"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="108018969"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial"><img alt="Research paper thumbnail of MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial" class="work-thumbnail" src="https://attachments.academia-assets.com/106517408/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial">MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, Oct 1, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d7178e2a1642324e9664d40e194eea4b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":106517408,"asset_id":108018969,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="108018969"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="108018969"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 108018969; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=108018969]").text(description); $(".js-view-count[data-work-id=108018969]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 108018969; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='108018969']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 108018969, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d7178e2a1642324e9664d40e194eea4b" } } $('.js-work-strip[data-work-id=108018969]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":108018969,"title":"MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"11.8Gy (1.0-20.4Gy), and lung V20 from 23.7% (1.5-47.8%) to 20.8% (1.2-39.7%). Reduced lung dose translated to reduced pneumonitis risk: from 8.6% (2.3-23.3%) to 6.5% (2.2-14.4%). Lung dose constraints were violated in 5/62 patients in FB and 1/62 patients in DIBH. Mean heart dose was reduced from 3.6Gy (0.1-25.8Gy) in FB to 2.4Gy (0.1-25.3Gy) in DIBH. DIBH reduced mean heart dose in 44/61 patients. The differences between FB and DIBH varied between e 6.6Gy and 8.9Gy, stressing the influence of tumour location on the potential of reducing heart dose with DIBH. Conclusion: Benefits of changed anatomy with DIBH were reduced dose to lungs and, for most patients, to the heart. Curative treatment intent could be maintained in more patients. Risk of developing radiation pneumonitis was reduced. Continuous follow up of INHALE patients will reveal how the reduced risk is manifested clinically.","publication_date":{"day":1,"month":10,"year":2018,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":106517408},"translated_abstract":null,"internal_url":"https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial","translated_internal_url":"","created_at":"2023-10-11T22:58:41.071-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":106517408,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517408/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517408/pdf-libre.pdf?1697091026=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=gzgFUO-r1eBpQjoGYpGsRAFS2pDqt2-9Oir3xptRi6gavFG2CJknGtnW097qu-ddr06V6CbDB8UrNW8QtQg66xdsbkA~NJabG62fyTUqKbYGjLwXYBSIHbJHNH7JV1lUIc37xD8gXr~tZjjkfRKAN13WcxXKS7Ez~-DXewkvBR8UOIHrEbh3m4mOQvcNA1TXYgyOzIKSfKU-GhiufmEfP0Z-ri-9AyA3cgzK~YzlrW-OVh6nwbDQm~HY4u7ZaVceZDyshXa4uOAvBzIKQSCSs~dLYPCEzyAI6aob~slFAyYenE38EfFp8gHrwjpL9BQAseMuknOOAYq21bk1GjNSoQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":106517408,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517408/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517408/pdf-libre.pdf?1697091026=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=gzgFUO-r1eBpQjoGYpGsRAFS2pDqt2-9Oir3xptRi6gavFG2CJknGtnW097qu-ddr06V6CbDB8UrNW8QtQg66xdsbkA~NJabG62fyTUqKbYGjLwXYBSIHbJHNH7JV1lUIc37xD8gXr~tZjjkfRKAN13WcxXKS7Ez~-DXewkvBR8UOIHrEbh3m4mOQvcNA1TXYgyOzIKSfKU-GhiufmEfP0Z-ri-9AyA3cgzK~YzlrW-OVh6nwbDQm~HY4u7ZaVceZDyshXa4uOAvBzIKQSCSs~dLYPCEzyAI6aob~slFAyYenE38EfFp8gHrwjpL9BQAseMuknOOAYq21bk1GjNSoQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":106517409,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517409/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517409/download_file","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517409/pdf-libre.pdf?1697091024=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=Epdih2qBYqv5mAZ2kg3tc8U9eyLGKHOubFPZsiT2dEondiBFIm46tM8qaw5BQtX~djYGzpghN5vDty9IV4HelmoKclcd2vLQt3Qu5EQu17Fjhw4nvHGKVKe13pXg~hl3FgCtuU3b54qP1woH2u1i6qrGpnQ1Of~An7UaJeR1wy6p78N-ZYi3KCScDu2W3qwN02Xd9DQhVSrCJMTIsUq80NHyrTyfDNvI0uIn3Q8NiFqpDoMjZQ7F4AsVFdUJpUeYuz1uJb5LdP8gYnPP3xKxQGXZ-DIwa~mUf7rkG9cXZdJkW3yzYw2DaqMoGcv6qM4MIoC~jETKeJB3nZwNpRyk4A__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":34621209,"url":"http://www.jto.org/article/S1556086418313121/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="108018966"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial"><img alt="Research paper thumbnail of High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial" class="work-thumbnail" src="https://attachments.academia-assets.com/106517433/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial">High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial</a></div><div class="wp-workCard_item"><span>The Lancet Oncology</span><span>, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="24faed3226b56309c6e652195fdf1987" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":106517433,"asset_id":108018966,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="108018966"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="108018966"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 108018966; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=108018966]").text(description); $(".js-view-count[data-work-id=108018966]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 108018966; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='108018966']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 108018966, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "24faed3226b56309c6e652195fdf1987" } } $('.js-work-strip[data-work-id=108018966]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":108018966,"title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"The Lancet Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial","translated_internal_url":"","created_at":"2023-10-11T22:58:40.429-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":106517433,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517433/thumbnails/1.jpg","file_name":"High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_.pdf","download_url":"https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"High_dose_versus_standard_dose_twice_dai.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517433/High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_-libre.pdf?1697091033=\u0026response-content-disposition=attachment%3B+filename%3DHigh_dose_versus_standard_dose_twice_dai.pdf\u0026Expires=1733051180\u0026Signature=I6UmcJl~JLubhf4lVj-hK-cirTqCNsZL1MkheHaNGELrcRd9xgawe9~GRW~~qv3RS-cnVHKXatSlZzYgtlXAXTQ3wMlcBb3IKtivL7kSdFVZB~349J6BfG3IxHYT3-xdJ0ND5h2b5BRgsWh6M4-crhU0jRLyOdkd30t2mr496LNh~GqvBOeE2xc~svO9DRat8wENxdtvG8FUChqjHVjehonL3WjP90G31gbU47zmwRbs0KKHbMUN0ZUQ6db25XOPAYyOknURmGlD-TglSZGL~KjascqLi4BZwAa6JSMDkIZdqPSwD2LNDgfBaLJHouha157e5zJfSx9WbzoC~ItwJw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial","translated_slug":"","page_count":16,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":106517433,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517433/thumbnails/1.jpg","file_name":"High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_.pdf","download_url":"https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"High_dose_versus_standard_dose_twice_dai.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517433/High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_-libre.pdf?1697091033=\u0026response-content-disposition=attachment%3B+filename%3DHigh_dose_versus_standard_dose_twice_dai.pdf\u0026Expires=1733051180\u0026Signature=I6UmcJl~JLubhf4lVj-hK-cirTqCNsZL1MkheHaNGELrcRd9xgawe9~GRW~~qv3RS-cnVHKXatSlZzYgtlXAXTQ3wMlcBb3IKtivL7kSdFVZB~349J6BfG3IxHYT3-xdJ0ND5h2b5BRgsWh6M4-crhU0jRLyOdkd30t2mr496LNh~GqvBOeE2xc~svO9DRat8wENxdtvG8FUChqjHVjehonL3WjP90G31gbU47zmwRbs0KKHbMUN0ZUQ6db25XOPAYyOknURmGlD-TglSZGL~KjascqLi4BZwAa6JSMDkIZdqPSwD2LNDgfBaLJHouha157e5zJfSx9WbzoC~ItwJw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":243630,"name":"Lancet Oncology","url":"https://www.academia.edu/Documents/in/Lancet_Oncology"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":2007840,"name":"Carboplatin","url":"https://www.academia.edu/Documents/in/Carboplatin"},{"id":2180163,"name":"Prophylactic Cranial Irradiation","url":"https://www.academia.edu/Documents/in/Prophylactic_Cranial_Irradiation"}],"urls":[{"id":34621207,"url":"https://api.elsevier.com/content/article/PII:S1470204520307427?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div><div class="profile--tab_content_container js-tab-pane tab-pane" data-section-id="4251624" id="papers"><div class="js-work-strip profile--work_container" data-work-id="125124512"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival"><img alt="Research paper thumbnail of Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival" class="work-thumbnail" src="https://attachments.academia-assets.com/119223677/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival">Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival</a></div><div class="wp-workCard_item"><span>International Archives of Otorhinolaryngology</span><span>, Sep 30, 2020</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d1d8520cf413381182105944dd41cecc" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":119223677,"asset_id":125124512,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="125124512"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="125124512"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 125124512; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=125124512]").text(description); $(".js-view-count[data-work-id=125124512]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 125124512; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='125124512']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 125124512, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d1d8520cf413381182105944dd41cecc" } } $('.js-work-strip[data-work-id=125124512]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":125124512,"title":"Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival","translated_title":"","metadata":{"publisher":"Thieme Revinter Publicações","grobid_abstract":"Introduction Head and neck cancer of unknown primary (HNCUP) is a rare condition whose prognostic factors that are significant for survival vary between studies. No randomized treatment study has been performed thus far, and the optimal treatment is not established. Objective The present study aimed to explore various prognostic factors and compare the two main treatments for HNCUP: neck dissection and (chemo) radiation vs primary (chemo) radiation. Methods A national multicenter study was performed with data from the Swedish Head and Neck Cancer Register (SweHNCR) and from the patients' medical records from 2008 to 2012. Results Two-hundred and sixty HNCUP patients were included. The tumors were HPVpositive in 80%. The overall 5-year survival rate of patients treated with curative intent was 71%. Age (p \u003c 0.001), performance status (p¼ 0.036), and N stage (p¼ 0.046) were significant factors for overall survival according to the multivariable analysis. Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups. Conclusions Age, performance status, and N stage were significant prognostic factors. Treatment with neck dissection and (chemo) radiation and primary (chemo) radiation gave similar survival outcomes. A randomized treatment study that includes quality of life is needed to establish the optimal treatment.","publication_date":{"day":30,"month":9,"year":2020,"errors":{}},"publication_name":"International Archives of Otorhinolaryngology","grobid_abstract_attachment_id":119223677},"translated_abstract":null,"internal_url":"https://www.academia.edu/125124512/Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival","translated_internal_url":"","created_at":"2024-10-28T22:28:07.181-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":119223677,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223677/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223677/s-0040-1712106-libre.pdf?1730181885=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=Jrx16dgcOQ3PXavQYUmlP126TqzzCOo~m1tqGtUqptkNYNzLgrO6sm8vWwLCIb2AB2j9yCncBxr9ucG2RP3VReOUTegoR~mLZlwcby0c86wk0Ai1Ul0pKTYBwOqVeoVTwWGo97-scql39l7khK-2E~QYksLxJtu6Pp7ORUtSIkzz9ZlIovFFEHgzk3VCmfRqpl6bRS0jlqOnhcWXS6sDEoT2pGbqd~49xAyLjtzpFjdoSaAFH~KifrzDmJuDLZCZuCFnZCOC-HDtAZRHO8SKqMpLMTfClRz-2xai8t7NfbtO9ykVTeTDhGLQI-ok8qu0CQeChc96Z7yTivdYZtokdw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_National_Multicenter_Study_on_Head_and_Neck_Cancer_of_Unknown_Primary_Prognostic_Factors_and_Impact_of_Treatment_on_Survival","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":119223677,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223677/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223677/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU3OSw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223677/s-0040-1712106-libre.pdf?1730181885=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=Jrx16dgcOQ3PXavQYUmlP126TqzzCOo~m1tqGtUqptkNYNzLgrO6sm8vWwLCIb2AB2j9yCncBxr9ucG2RP3VReOUTegoR~mLZlwcby0c86wk0Ai1Ul0pKTYBwOqVeoVTwWGo97-scql39l7khK-2E~QYksLxJtu6Pp7ORUtSIkzz9ZlIovFFEHgzk3VCmfRqpl6bRS0jlqOnhcWXS6sDEoT2pGbqd~49xAyLjtzpFjdoSaAFH~KifrzDmJuDLZCZuCFnZCOC-HDtAZRHO8SKqMpLMTfClRz-2xai8t7NfbtO9ykVTeTDhGLQI-ok8qu0CQeChc96Z7yTivdYZtokdw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":119223676,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/119223676/thumbnails/1.jpg","file_name":"s-0040-1712106.pdf","download_url":"https://www.academia.edu/attachments/119223676/download_file","bulk_download_file_name":"Swedish_National_Multicenter_Study_on_He.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/119223676/s-0040-1712106-libre.pdf?1730181886=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_National_Multicenter_Study_on_He.pdf\u0026Expires=1733051179\u0026Signature=gK~QwMZVb2MxHrq33-sunFLDZKBRInMd8qD72JKR3GRcl-3UOpLxdsysBh4dAiYbyUNWzELlMRtBp4uVbT-hCj3qeif2RbbdC5lwfw2xcSqHYSrnAfIqXEk00Bweflf~q6-Xdce4kvHHK~dUfUwS6L04a3OWd9kghRVVT0QMcH6gUjkb-owCwgQLqpyaeZF6GCIfcwzTOl6M0xa2n~HahV0OU71aaNjH-Di46DyMBXWQGXS3EGd28b1tSN8fslLF-mGnj0iTrQRNylfwFKj2fyv8XXAHnlk160-AG8w-IXkl8nyWKWcpR3lmgxOc7aE8pxjCaWYf6JzzDEzQy9nMMQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":647,"name":"Surgery","url":"https://www.academia.edu/Documents/in/Surgery"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":53661,"name":"Head and Neck","url":"https://www.academia.edu/Documents/in/Head_and_Neck"},{"id":98549,"name":"Head and Neck Cancer","url":"https://www.academia.edu/Documents/in/Head_and_Neck_Cancer"},{"id":1225372,"name":"Overall Survival","url":"https://www.academia.edu/Documents/in/Overall_Survival"},{"id":3194190,"name":"Neck dissection","url":"https://www.academia.edu/Documents/in/Neck_dissection"}],"urls":[{"id":45376750,"url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1712106.pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504849"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy"><img alt="Research paper thumbnail of Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy">Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy</a></div><div class="wp-workCard_item"><span>PubMed</span><span>, Oct 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation p...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504849"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504849"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504849; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504849]").text(description); $(".js-view-count[data-work-id=114504849]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504849; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504849']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504849, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504849]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504849,"title":"Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy","translated_title":"","metadata":{"abstract":"Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.","publication_date":{"day":1,"month":10,"year":2015,"errors":{}},"publication_name":"PubMed"},"translated_abstract":"Aim: To elucidate the impact of different forms of radiation toxicities (esophagitis, radiation pneumonitis, mucositis and hoarseness), on the survival of patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Data were individually collected retrospectively for all patients diagnosed with NSCLC subjected to curatively intended radiotherapy (≥50 Gy) in Sweden during the time period 1990 to 2000. Results: Esophagitis was the only radiation-induced toxicity with an impact on survival (hazard ratio=0.83, p=0.016). However, in a multivariate model, with clinical- and treatment-related factors taken into consideration, the impact of esophagitis on survival was no longer statistically significant (hazard ratio=0.88, p=0.17). Conclusion: The effect on survival seen in univariate analysis may be related to higher radiation dose and to the higher prevalence of chemotherapy in this group. The results do not suggest that the toxicities examined have any detrimental effect on overall survival.","internal_url":"https://www.academia.edu/114504849/Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:09.592-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Effect_of_Increased_Radiotoxicity_on_Survival_of_Patients_with_Non_small_Cell_Lung_Cancer_Treated_with_Curatively_Intended_Radiotherapy","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":98939,"name":"Pubmed","url":"https://www.academia.edu/Documents/in/Pubmed"},{"id":189574,"name":"Mucositis","url":"https://www.academia.edu/Documents/in/Mucositis"},{"id":263843,"name":"Anticancer","url":"https://www.academia.edu/Documents/in/Anticancer"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1745478,"name":"Adenocarcinoma","url":"https://www.academia.edu/Documents/in/Adenocarcinoma"},{"id":1971418,"name":"Esophagitis","url":"https://www.academia.edu/Documents/in/Esophagitis"},{"id":2464960,"name":"Pneumonitis","url":"https://www.academia.edu/Documents/in/Pneumonitis"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206135,"url":"https://pubmed.ncbi.nlm.nih.gov/26408714"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504848"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy"><img alt="Research paper thumbnail of The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186095/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy">The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy</a></div><div class="wp-workCard_item"><span>PubMed</span><span>, Apr 1, 2012</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Aim: The aim of the present study was to retrospectively investigate the impact of induction chem...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="cd782d58f508ffd8ea0a056c0648a5d1" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186095,"asset_id":114504848,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504848"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504848"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504848; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504848]").text(description); $(".js-view-count[data-work-id=114504848]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504848; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504848']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504848, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "cd782d58f508ffd8ea0a056c0648a5d1" } } $('.js-work-strip[data-work-id=114504848]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504848,"title":"The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy","translated_title":"","metadata":{"abstract":"Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.","publication_date":{"day":1,"month":4,"year":2012,"errors":{}},"publication_name":"PubMed"},"translated_abstract":"Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (≥50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.","internal_url":"https://www.academia.edu/114504848/The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:09.300-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186095,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186095/thumbnails/1.jpg","file_name":"1339.full.pdf","download_url":"https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_induction_chemotherapy_for.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186095/1339.full-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_induction_chemotherapy_for.pdf\u0026Expires=1733027654\u0026Signature=Dg-E8xnITFXbHaIr7SGXR8mtOgUPVuhdYPq~Ney~ICfi0x0AXIXnWVs9oxu9DG~QE5WO5auDl6SQo5X4l6-V~GhLlH2Ke2J4adnf4GYRDAm3RXdnp03Yg~Btn5hU2bqvdAT8zB6GbbjLQV4e4Roo6KJDbOLlzJbmPt~FlTziWwoPfUJyPEZ8oPIxjVo4imCtR1KPMejZJVrAffdn2SVRnLu8voFxc9dbcJPHwzQ2pE8X9ABSigk3qrkmT4U4xajM3rQTQ2GmivNnFgC~mquPT8TRwb5JCWv~9ODmDuWfuc3CjddRxQw5RZDmtHFVYkTko3lPnGZW5xSj3ftgIlJYOw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_value_of_induction_chemotherapy_for_survival_in_patients_with_non_small_cell_lung_cancer_treated_with_radiotherapy","translated_slug":"","page_count":8,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186095,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186095/thumbnails/1.jpg","file_name":"1339.full.pdf","download_url":"https://www.academia.edu/attachments/111186095/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_induction_chemotherapy_for.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186095/1339.full-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_induction_chemotherapy_for.pdf\u0026Expires=1733027654\u0026Signature=Dg-E8xnITFXbHaIr7SGXR8mtOgUPVuhdYPq~Ney~ICfi0x0AXIXnWVs9oxu9DG~QE5WO5auDl6SQo5X4l6-V~GhLlH2Ke2J4adnf4GYRDAm3RXdnp03Yg~Btn5hU2bqvdAT8zB6GbbjLQV4e4Roo6KJDbOLlzJbmPt~FlTziWwoPfUJyPEZ8oPIxjVo4imCtR1KPMejZJVrAffdn2SVRnLu8voFxc9dbcJPHwzQ2pE8X9ABSigk3qrkmT4U4xajM3rQTQ2GmivNnFgC~mquPT8TRwb5JCWv~9ODmDuWfuc3CjddRxQw5RZDmtHFVYkTko3lPnGZW5xSj3ftgIlJYOw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":10610,"name":"Survival Analysis","url":"https://www.academia.edu/Documents/in/Survival_Analysis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":66080,"name":"Age","url":"https://www.academia.edu/Documents/in/Age"},{"id":98939,"name":"Pubmed","url":"https://www.academia.edu/Documents/in/Pubmed"},{"id":263843,"name":"Anticancer","url":"https://www.academia.edu/Documents/in/Anticancer"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1281465,"name":"Univariate Analysis","url":"https://www.academia.edu/Documents/in/Univariate_Analysis"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"},{"id":4320322,"name":"hazard ratio","url":"https://www.academia.edu/Documents/in/hazard_ratio"}],"urls":[{"id":39206134,"url":"https://pubmed.ncbi.nlm.nih.gov/22493368"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504846"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186130/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer">Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>European Journal of Cancer</span><span>, Nov 1, 2011</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="61cdc8d2abb71efdc2d1c2a6ddc130df" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186130,"asset_id":114504846,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504846"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504846"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504846; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504846]").text(description); $(".js-view-count[data-work-id=114504846]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504846; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504846']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504846, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "61cdc8d2abb71efdc2d1c2a6ddc130df" } } $('.js-work-strip[data-work-id=114504846]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504846,"title":"Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"j o u r n a l h o m e p a g e : w w w. e j c o n l i n e. c o m after curatively intended radiation therapy in comparison with squamous cell carcinoma patients, particularly those with clinical stages IIA-IIB.","publication_date":{"day":1,"month":11,"year":2011,"errors":{}},"publication_name":"European Journal of Cancer","grobid_abstract_attachment_id":111186130},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504846/Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:08.220-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186130,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186130/thumbnails/1.jpg","file_name":"j.ejca.2011.06.01120240205-1-229v36.pdf","download_url":"https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_Lung_Cancer_Radiation_Study_Grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186130/j.ejca.2011.06.01120240205-1-229v36-libre.pdf?1707145115=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_Lung_Cancer_Radiation_Study_Grou.pdf\u0026Expires=1733051180\u0026Signature=RDXXqk4F95ULUz1j-un6PFaqUYqlHKUPWEsoL-kPZGId3too47VwO1x2u3wO3IgkFc9tuiP~dsYbrx~ang6RNEbRzOG1rIw0MFHaqpwtVQv~uyfurttdT2paXJ4zbpd3DKeFsV3Z-5asY-UvWjJc9hUJjKE0F1pmCkyHdNDFSOHksOYhPmlU5enVCYv6TOtL1YOt3Vjc0t5ywmjEeJqYpNhRB7ki1-yWD15y1JjHG6o0AS9FoSPurd6RIRlxJ2LX0w8vVOp1Tf9xOsHuGQ5O8JCG8K0RJbEsCSaSe9mXeOpUQ7Z1Y-~Bm-7SfC4W7YGsI6hZgbFF-criHc29Aj4juA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_Lung_Cancer_Radiation_Study_Group_Predictive_value_of_histology_for_radiotherapy_response_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186130,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186130/thumbnails/1.jpg","file_name":"j.ejca.2011.06.01120240205-1-229v36.pdf","download_url":"https://www.academia.edu/attachments/111186130/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_Lung_Cancer_Radiation_Study_Grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186130/j.ejca.2011.06.01120240205-1-229v36-libre.pdf?1707145115=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_Lung_Cancer_Radiation_Study_Grou.pdf\u0026Expires=1733051180\u0026Signature=RDXXqk4F95ULUz1j-un6PFaqUYqlHKUPWEsoL-kPZGId3too47VwO1x2u3wO3IgkFc9tuiP~dsYbrx~ang6RNEbRzOG1rIw0MFHaqpwtVQv~uyfurttdT2paXJ4zbpd3DKeFsV3Z-5asY-UvWjJc9hUJjKE0F1pmCkyHdNDFSOHksOYhPmlU5enVCYv6TOtL1YOt3Vjc0t5ywmjEeJqYpNhRB7ki1-yWD15y1JjHG6o0AS9FoSPurd6RIRlxJ2LX0w8vVOp1Tf9xOsHuGQ5O8JCG8K0RJbEsCSaSe9mXeOpUQ7Z1Y-~Bm-7SfC4W7YGsI6hZgbFF-criHc29Aj4juA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":12069,"name":"Histology","url":"https://www.academia.edu/Documents/in/Histology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":212690,"name":"Non small cell carcinoma","url":"https://www.academia.edu/Documents/in/Non_small_cell_carcinoma"},{"id":279027,"name":"European","url":"https://www.academia.edu/Documents/in/European"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":410532,"name":"Clinical Data","url":"https://www.academia.edu/Documents/in/Clinical_Data"},{"id":1225372,"name":"Overall Survival","url":"https://www.academia.edu/Documents/in/Overall_Survival"},{"id":1548118,"name":"Non small Cell Lung Cancer","url":"https://www.academia.edu/Documents/in/Non_small_Cell_Lung_Cancer"},{"id":1745478,"name":"Adenocarcinoma","url":"https://www.academia.edu/Documents/in/Adenocarcinoma"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206132,"url":"https://doi.org/10.1016/j.ejca.2011.06.011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504845"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC"><img alt="Research paper thumbnail of How to improve loco-regional control in stages IIIa–b NSCLC?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC">How to improve loco-regional control in stages IIIa–b NSCLC?</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Jul 1, 2009</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-sma...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS&amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504845"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504845"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504845; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504845]").text(description); $(".js-view-count[data-work-id=114504845]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504845; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504845']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504845, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504845]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504845,"title":"How to improve loco-regional control in stages IIIa–b NSCLC?","translated_title":"","metadata":{"abstract":"A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS\u0026amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.","publisher":"Elsevier BV","publication_date":{"day":1,"month":7,"year":2009,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":"A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested. Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies. Inoperable stage III non-small cell lung cancer patients in good performance status (PS\u0026amp;lt;2) were equally randomized to either of three arms in eight institutions. All arms started with two cycles of induction chemotherapy: paclitaxel 200 mg/m2 and carboplatin AUC6. Arm A: a third identical cycle was given concomitant with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy: 2 Gy to 60 Gy in 6 weeks. Arm C: weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy. Primary endpoint: TTP. Secondary: OS, toxicity, QL and relapse pattern. Between June 2002 and May 2005 152 patients were randomized and of them 151 were evaluable: 78 men and 73 women, median age 62 years (43-78), 55% had performance status 0 and 45% PS 1. Thirty-four percent had stage IIIa and 66% IIIb. adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma. The three arms were well balanced. Toxicity was manageable with 12% grades 3-4 esophagitis, 1% grades 3-4 pneumonitis and there was no clear difference between the arms. The QL data did not differ either. Median time to progression was 9.8 (8.3-12.7) months (8.8, 10.3 and 9.3 months for arms A, B and C, respectively). Median survival was 17.8 (14.4-23.7) months (17.7, 17.7 and 20.6 months for A, B and C, respectively). The 1-, 3- and 5-year overall survival was 63, 31 and 24%. Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms. Thirty-four percent developed brain metastases. Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concomitant chemo-radiotherapy both in terms of survival, toxicity and quality of life. The optimal treatment schedule for patients with locally advanced NSCLC is still to be decided and investigated in future clinical studies. Relapse pattern with distant metastases and especially brain metastases is a great problem and need further research for better therapy options and higher cure rate for this patient group.","internal_url":"https://www.academia.edu/114504845/How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC","translated_internal_url":"","created_at":"2024-02-05T05:55:07.850-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"How_to_improve_loco_regional_control_in_stages_IIIa_b_NSCLC","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":7523,"name":"Control","url":"https://www.academia.edu/Documents/in/Control"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":97056,"name":"Clinical Medicine","url":"https://www.academia.edu/Documents/in/Clinical_Medicine"},{"id":128538,"name":"Arm","url":"https://www.academia.edu/Documents/in/Arm"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1548118,"name":"Non small Cell Lung Cancer","url":"https://www.academia.edu/Documents/in/Non_small_Cell_Lung_Cancer"},{"id":1938454,"name":"Adverse effects","url":"https://www.academia.edu/Documents/in/Adverse_effects"},{"id":2007840,"name":"Carboplatin","url":"https://www.academia.edu/Documents/in/Carboplatin"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206131,"url":"https://doi.org/10.1016/j.lungcan.2008.10.021"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504844"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group">Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Feb 1, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Several attempts to increase the locoregional control in locally advanced lung cancer including c...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1&amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss&amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504844"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504844"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504844; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504844]").text(description); $(".js-view-count[data-work-id=114504844]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504844; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504844']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504844, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504844]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504844,"title":"Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"abstract":"Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1\u0026amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss\u0026amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.","publisher":"Elsevier BV","publication_date":{"day":1,"month":2,"year":2011,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":"Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cetuximab has shown activity concurrent with radiotherapy in squamous cell carcinoma of the head and neck, as well as in stage IV NSCLC combined with chemotherapy, we wanted to investigate radiotherapy with concurrent cetuximab in locally advanced NSCLC, a tumour type often over expressing the EGF-receptor. Between February 2006 and August 2007 75 patients in stage III NSCLC with good performance status (PS 0 or 1) and adequate lung function (FEV1\u0026amp;gt;1.0) were enrolled in this phase II study at eight institutions. Treatment consisted of 2 cycles of induction chemotherapy, docetaxel 75 mg/m² and cisplatin 75 mg/m² with 3 weeks interval. An initial dose of cetuximab 400 mg/m² was given before start of 3D-CRT to 68 Gy with 2 Gy per fraction in 7 weeks concurrent with weekly cetuximab 250 mg/m². TOXICITY was scored weekly during radiotherapy (CTC 3.0), and after treatment the patients were followed every third month with CT-scans, toxicity scoring and QLQ. Seventy-one patients were eligible for analysis as four were incorrectly enrolled. adenocarcinoma 49%, squamous cell carcinoma 39% and other NSCLC 12%. The majority had PS 0 (62.5%), median age 62.2 (42-81), 50% were women and 37% had a pre-treatment weight loss\u0026amp;gt;5%. esophagitis grade 1-2: 72%; grade 3: 1.4%. Hypersensitivity reactions grade 3-4: 5.6%. Febrile neutropenia grade 3-4: 15.4%. Skin reactions grade 1-2: 74%; grade 3: 4.2%. Diarrhoea grade 1-2: 38%; grade 3: 11.3%. Pneumonitis grade 1-2: 26.8%; grade 3: 4.2%; grade 5: 1.4%. The median follow-up was 39 months for patients alive and the median survival was 17 months with a 1-, 2- and 3-year OS of 66%, 37% and 29% respectively. Until now local or regional failure has occurred in 20 patients and 22 patients have developed distant metastases. Weight loss, PS and stage were predictive for survival in univariate as well as in multivariate analysis. Induction chemotherapy followed by concurrent cetuximab and RT to 68 Gy is clearly feasible with promising survival. TOXICITY, e.g. pneumonitis and esophagitis is low compared to most schedules with concurrent chemotherapy. This treatment strategy should be evaluated in a randomised manner vs. concurrent chemoradiotherapy to find out if it is a valid treatment option.","internal_url":"https://www.academia.edu/114504844/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:07.603-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_Satellite_A_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":53661,"name":"Head and Neck","url":"https://www.academia.edu/Documents/in/Head_and_Neck"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":276781,"name":"Cisplatin","url":"https://www.academia.edu/Documents/in/Cisplatin"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1128165,"name":"EGF receptor","url":"https://www.academia.edu/Documents/in/EGF_receptor"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2326675,"name":"Docetaxel","url":"https://www.academia.edu/Documents/in/Docetaxel"},{"id":2463779,"name":"Combined Modality Therapy","url":"https://www.academia.edu/Documents/in/Combined_Modality_Therapy"},{"id":3703401,"name":"Locally advanced","url":"https://www.academia.edu/Documents/in/Locally_advanced"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206130,"url":"https://doi.org/10.1016/j.lungcan.2010.05.011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504843"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials"><img alt="Research paper thumbnail of Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials" class="work-thumbnail" src="https://attachments.academia-assets.com/111186120/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials">Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, Jul 1, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c17f6d5d01463d606906c2c58acac0a0" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186120,"asset_id":114504843,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504843"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504843"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504843; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504843]").text(description); $(".js-view-count[data-work-id=114504843]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504843; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504843']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504843, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c17f6d5d01463d606906c2c58acac0a0" } } $('.js-work-strip[data-work-id=114504843]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504843,"title":"Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – Pooled results from two prospective clinical trials","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Physical/role functioning improved 6 months after concurrent chemoradiation (CCRT)/radiation (RT) + radical surgery (RS). • Tumor-related symptoms of fatigue and insomnia decreased 6 months after treatment. • Treatment-related symptoms of lymphedema and menopausal symptoms increased after treatment. • Sexuality was not impaired significantly except for a worsened sexual worry in the RT + RS group. • Generally RT + RS seems superior to CCRT+RS with greater improvement in functioning and less toxicity.","publication_date":{"day":1,"month":7,"year":2012,"errors":{}},"publication_name":"Radiotherapy and Oncology","grobid_abstract_attachment_id":111186120},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504843/Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials","translated_internal_url":"","created_at":"2024-02-05T05:55:07.338-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186120,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186120/thumbnails/1.jpg","file_name":"j.ygyno.2019.07.00520240205-1-tud1hw.pdf","download_url":"https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Health_related_quality_of_life_in_locall.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186120/j.ygyno.2019.07.00520240205-1-tud1hw-libre.pdf?1707145120=\u0026response-content-disposition=attachment%3B+filename%3DHealth_related_quality_of_life_in_locall.pdf\u0026Expires=1733051180\u0026Signature=Irk40IyXmZRAAy55xdeyqVaLP5SKhZr9uP7~sxfhVutBHZuO~Jhwjj9JzXfCZhk3Gw-Y2HO71z~2dP3~48xJKgggJgF2vnk2XeTtaoEbXttFE-UyllIirebhyLiuv3JogcN5CWTh6OVEVugtZm8om17E1l-hGhPrctboj8sm1bjit2nCCuhwMP7-x5T~IYdAGXf79dScXfFIMvLYtOdSoZLLnSdoTZNeJUhIBScN1kOtoqQY6gLAGijFqxnfqZYzrrJz2JMuvUjrT39ODmzYUBFhmU~HS452gIU4ViSNIfXwwaefMCbeybgs4ZFln2kV0PAGaUdcgYXsAR89ARYsPQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Health_related_quality_of_life_in_locally_advanced_NSCLC_treated_with_high_dose_radiotherapy_and_concurrent_chemotherapy_or_cetuximab_Pooled_results_from_two_prospective_clinical_trials","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186120,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186120/thumbnails/1.jpg","file_name":"j.ygyno.2019.07.00520240205-1-tud1hw.pdf","download_url":"https://www.academia.edu/attachments/111186120/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Health_related_quality_of_life_in_locall.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186120/j.ygyno.2019.07.00520240205-1-tud1hw-libre.pdf?1707145120=\u0026response-content-disposition=attachment%3B+filename%3DHealth_related_quality_of_life_in_locall.pdf\u0026Expires=1733051180\u0026Signature=Irk40IyXmZRAAy55xdeyqVaLP5SKhZr9uP7~sxfhVutBHZuO~Jhwjj9JzXfCZhk3Gw-Y2HO71z~2dP3~48xJKgggJgF2vnk2XeTtaoEbXttFE-UyllIirebhyLiuv3JogcN5CWTh6OVEVugtZm8om17E1l-hGhPrctboj8sm1bjit2nCCuhwMP7-x5T~IYdAGXf79dScXfFIMvLYtOdSoZLLnSdoTZNeJUhIBScN1kOtoqQY6gLAGijFqxnfqZYzrrJz2JMuvUjrT39ODmzYUBFhmU~HS452gIU4ViSNIfXwwaefMCbeybgs4ZFln2kV0PAGaUdcgYXsAR89ARYsPQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":62112,"name":"Prospective studies","url":"https://www.academia.edu/Documents/in/Prospective_studies"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":147196,"name":"Monoclonal Antibodies","url":"https://www.academia.edu/Documents/in/Monoclonal_Antibodies"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":1212103,"name":"Antineoplastic Agents","url":"https://www.academia.edu/Documents/in/Antineoplastic_Agents"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2463778,"name":"Clinical Trials as Topic","url":"https://www.academia.edu/Documents/in/Clinical_Trials_as_Topic"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206129,"url":"https://doi.org/10.1016/j.radonc.2012.05.006"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504842"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group">Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, 2009</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504842"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504842"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504842; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504842]").text(description); $(".js-view-count[data-work-id=114504842]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504842; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504842']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504842, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504842]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504842,"title":"Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2009,"errors":{}},"publication_name":"Journal of Thoracic Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504842/Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:07.091-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Concurrent_cetuximab_and_radiotherapy_after_docetaxel_cisplatin_induction_chemotherapy_in_stage_III_NSCLC_a_phase_II_study_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":9114,"name":"Chemotherapy","url":"https://www.academia.edu/Documents/in/Chemotherapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":276781,"name":"Cisplatin","url":"https://www.academia.edu/Documents/in/Cisplatin"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":1217404,"name":"Cetuximab","url":"https://www.academia.edu/Documents/in/Cetuximab"},{"id":2326675,"name":"Docetaxel","url":"https://www.academia.edu/Documents/in/Docetaxel"}],"urls":[{"id":39206128,"url":"https://lup.lub.lu.se/search/publication/c99afce8-9ad1-4bc9-94cd-dc9e6822d10b"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504841"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group"><img alt="Research paper thumbnail of PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group" class="work-thumbnail" src="https://attachments.academia-assets.com/111186083/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group">PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, Aug 1, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="2b0ad3aed07e251711d0a7cef7639404" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186083,"asset_id":114504841,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504841"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504841"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504841; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504841]").text(description); $(".js-view-count[data-work-id=114504841]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504841; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504841']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504841, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "2b0ad3aed07e251711d0a7cef7639404" } } $('.js-work-strip[data-work-id=114504841]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504841,"title":"PD4-1-3: How to improve loco-regional control in stage IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Background: Induction chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to","publication_date":{"day":1,"month":8,"year":2007,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":111186083},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504841/PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group","translated_internal_url":"","created_at":"2024-02-05T05:55:06.807-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186083,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186083/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"PD4_1_3_How_to_improve_loco_regional_con.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186083/pdf-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPD4_1_3_How_to_improve_loco_regional_con.pdf\u0026Expires=1733027655\u0026Signature=DtVHa9sHxnHh8OVyn5d~eLWFMqaLkDzZFs-qvpGYdgpZq2Gmc~oOCe6JzD6xZqt96vlfvKEqUVKcWO6989RqIDuR3Fz3CI65LHGRkF9-TcEjMsHF~y2dJ9NuUhK0VoarP9KihHmxdw0FImuOkcff~ZFeiqnfS4eI2z0bpbMojOKivo2ZxvkbLphZB2YflpcdnUXrbNL6juqA5e8IO6Ia4~fanixOQlcwIf0UnAepRtEYWQkinVnVh1n79j~tWH12lagp~kLfLFZjTQ5HbcLQ59ZI6chmUSLzGZIWxR3V7lONtnCbxGRnY9Q2ZDmAnr~28qeygf9YY~0xwdPRRWj-jQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"PD4_1_3_How_to_improve_loco_regional_control_in_stage_IIIa_b_NSCLC_Results_of_a_three_armed_randomized_trial_from_the_Swedish_Lung_Cancer_Study_Group","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186083,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186083/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111186083/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"PD4_1_3_How_to_improve_loco_regional_con.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186083/pdf-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPD4_1_3_How_to_improve_loco_regional_con.pdf\u0026Expires=1733027655\u0026Signature=DtVHa9sHxnHh8OVyn5d~eLWFMqaLkDzZFs-qvpGYdgpZq2Gmc~oOCe6JzD6xZqt96vlfvKEqUVKcWO6989RqIDuR3Fz3CI65LHGRkF9-TcEjMsHF~y2dJ9NuUhK0VoarP9KihHmxdw0FImuOkcff~ZFeiqnfS4eI2z0bpbMojOKivo2ZxvkbLphZB2YflpcdnUXrbNL6juqA5e8IO6Ia4~fanixOQlcwIf0UnAepRtEYWQkinVnVh1n79j~tWH12lagp~kLfLFZjTQ5HbcLQ59ZI6chmUSLzGZIWxR3V7lONtnCbxGRnY9Q2ZDmAnr~28qeygf9YY~0xwdPRRWj-jQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":203752,"name":"Randomized Trial","url":"https://www.academia.edu/Documents/in/Randomized_Trial"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":413196,"name":"Randomized Controlled Trial","url":"https://www.academia.edu/Documents/in/Randomized_Controlled_Trial"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":39206127,"url":"https://doi.org/10.1097/01.jto.0000283373.63338.99"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504840"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_"><img alt="Research paper thumbnail of P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_">P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?</a></div><div class="wp-workCard_item"><span>Lung Cancer</span><span>, Jul 1, 2005</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504840"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504840"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504840; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504840]").text(description); $(".js-view-count[data-work-id=114504840]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504840; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504840']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504840, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504840]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504840,"title":"P-767 Is the total dose of importance in thoracic radiotherapy ofsmall-cell lung cancer (SCLC) limited disease (LD)?","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":7,"year":2005,"errors":{}},"publication_name":"Lung Cancer"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504840/P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_","translated_internal_url":"","created_at":"2024-02-05T05:55:06.427-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"P_767_Is_the_total_dose_of_importance_in_thoracic_radiotherapy_ofsmall_cell_lung_cancer_SCLC_limited_disease_LD_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":99773,"name":"Disease","url":"https://www.academia.edu/Documents/in/Disease"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"}],"urls":[{"id":39206126,"url":"https://doi.org/10.1016/s0169-5002(05)81260-7"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504839"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186085/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer">The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>Medical Oncology</span><span>, Dec 18, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d60d2ad65180401d664dfc306650381a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186085,"asset_id":114504839,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504839"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504839"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504839; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504839]").text(description); $(".js-view-count[data-work-id=114504839]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504839; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504839']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504839, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d60d2ad65180401d664dfc306650381a" } } $('.js-work-strip[data-work-id=114504839]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504839,"title":"The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Springer Science+Business Media","grobid_abstract":"The prognosis for patients with lung cancer is poor with an average of 5-year overall survival rate of only 10-15 % taking all clinical stages together. The aim of this study was to elucidate the impact of the radiotherapy regimen on survival. Clinical data were collected from all the Swedish Oncology Departments for 1,287 patients with a diagnosed non-small cell lung cancer (NSCLC) subjected to curatively intended irradiation (C50 Gy) during the years 1990 to 2000. The included patients were identified based on a manual search of all medical and radiation charts at the oncology departments from which the individual patient data were collected. Patients who did not have a histopathological diagnosis date and/or death date/ last follow-up date as well as patients being surgically treated were excluded from the study (n = 592). Thus, 695","publication_date":{"day":18,"month":12,"year":2012,"errors":{}},"publication_name":"Medical Oncology","grobid_abstract_attachment_id":111186085},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504839/The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:05.979-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186085,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186085/thumbnails/1.jpg","file_name":"s12032-012-0320-y20240205-1-au4b5x.pdf","download_url":"https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_impact_of_hyperfractionated_radiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186085/s12032-012-0320-y20240205-1-au4b5x-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DThe_impact_of_hyperfractionated_radiothe.pdf\u0026Expires=1733027655\u0026Signature=UqgzqWikdWl7zjLhCFZveu0Si5fLAr7IzaL7B4d9k4JCO2U0zh1dv5VIf~-OzOlT0dJTxHLQ9kuj7Nw9dzRodo1i9EyRGFgD~1imjKbl-UcS0gCjd0U7P1lt8i9hb0e8O~RmPg6lR29zg3BkhTeyHhoqeSWav~gHGHPxkAzSCwTNP~Y9jAC3Ukghd1AVNNJaFMWycoWhbNYoSBhdD84xSTL3l9uXOj2CBbXvK~iYbislWno60V9rUJfelMn42X5NMETX-IWT7l0ZJo6Vf5sr~Y1nt~C6uH2UP3lRRwyxR9AHZwSahQf3SqcihxBAUnuuzDoUIX4jQ4XmLhoSX88pxQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_impact_of_hyperfractionated_radiotherapy_regimen_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186085,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186085/thumbnails/1.jpg","file_name":"s12032-012-0320-y20240205-1-au4b5x.pdf","download_url":"https://www.academia.edu/attachments/111186085/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_impact_of_hyperfractionated_radiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186085/s12032-012-0320-y20240205-1-au4b5x-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DThe_impact_of_hyperfractionated_radiothe.pdf\u0026Expires=1733027655\u0026Signature=UqgzqWikdWl7zjLhCFZveu0Si5fLAr7IzaL7B4d9k4JCO2U0zh1dv5VIf~-OzOlT0dJTxHLQ9kuj7Nw9dzRodo1i9EyRGFgD~1imjKbl-UcS0gCjd0U7P1lt8i9hb0e8O~RmPg6lR29zg3BkhTeyHhoqeSWav~gHGHPxkAzSCwTNP~Y9jAC3Ukghd1AVNNJaFMWycoWhbNYoSBhdD84xSTL3l9uXOj2CBbXvK~iYbislWno60V9rUJfelMn42X5NMETX-IWT7l0ZJo6Vf5sr~Y1nt~C6uH2UP3lRRwyxR9AHZwSahQf3SqcihxBAUnuuzDoUIX4jQ4XmLhoSX88pxQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":4531,"name":"Clinical Trial","url":"https://www.academia.edu/Documents/in/Clinical_Trial"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":64900,"name":"Medical Oncology","url":"https://www.academia.edu/Documents/in/Medical_Oncology"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":1034951,"name":"Regimen","url":"https://www.academia.edu/Documents/in/Regimen"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"},{"id":1740333,"name":"Hyperfractionation","url":"https://www.academia.edu/Documents/in/Hyperfractionation"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206125,"url":"https://doi.org/10.1007/s12032-012-0320-y"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504838"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply"><img alt="Research paper thumbnail of Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply">Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply</a></div><div class="wp-workCard_item"><span>Lancet Oncology</span><span>, Jun 1, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504838"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504838"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504838; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504838]").text(description); $(".js-view-count[data-work-id=114504838]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504838; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504838']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504838, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504838]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504838,"title":"Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":6,"year":2021,"errors":{}},"publication_name":"Lancet Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504838/Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply","translated_internal_url":"","created_at":"2024-02-05T05:55:05.677-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Twice_daily_chemoradiotherapy_in_limited_stage_small_cell_lung_cancer_Authors_reply","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":626,"name":"Oncology","url":"https://www.academia.edu/Documents/in/Oncology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":243630,"name":"Lancet Oncology","url":"https://www.academia.edu/Documents/in/Lancet_Oncology"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"}],"urls":[{"id":39206124,"url":"https://doi.org/10.1016/s1470-2045(21)00291-6"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504837"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer"><img alt="Research paper thumbnail of OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186092/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer">OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, Apr 1, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="249bdab42652a70f05acd773b670c172" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186092,"asset_id":114504837,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504837"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504837"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504837; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504837]").text(description); $(".js-view-count[data-work-id=114504837]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504837; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504837']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504837, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "249bdab42652a70f05acd773b670c172" } } $('.js-work-strip[data-work-id=114504837]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504837,"title":"OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Using median C20 to stratify the patient data resulted in two significantly different survival distributions when all calcifications were used (p=0.003, log-rank test) but borderline for calcifications only in the heart. Figure 2 shows the corresponding Kaplan-Meier survival estimates. Conclusion Our results suggest that the risk of death increases by 27% for every extra cm 3 of calcifications receiving at least 20 Gy. Moreover, the loss of significance when analysing data to only the calcifications within the heart suggest an important dose/effect relation for calcifications outside the heart and these should not be ignored. We are planning to validate of our findings in an external cohort. OC-0405 Registry-based modelling of early mortality following radiotherapy of lung cancer","publication_date":{"day":1,"month":4,"year":2019,"errors":{}},"publication_name":"Radiotherapy and Oncology","grobid_abstract_attachment_id":111186092},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504837/OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:55:05.433-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186092,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186092/thumbnails/1.jpg","file_name":"s0167-814028192930825-420240205-1-54058o.pdf","download_url":"https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"OC_0405_Registry_based_modelling_of_earl.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186092/s0167-814028192930825-420240205-1-54058o-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DOC_0405_Registry_based_modelling_of_earl.pdf\u0026Expires=1733027655\u0026Signature=UMAYxhPA3g86ud~YSu5HXSvlz3m~y9YZOICHmlYoB-sOD112Gr0JeaGw3R4ej8l0YL1dfmU0aPohEOmEP4rJMBWAqWnlP5z1Zn4qFz-M22ba937aOSobIKgN~SaWZlNzkCNc0r9TzfL3879lIBFAbKDlsBszJFwiI3xvPdhpqrmJoP~dqeT4iyywZcRX45IBVAdN8NN6S--P52mghVzeHjrsn69Mdg-IF0hXST7TCRgV80PeTHTgauuUQmqTlaW60yEqmlFvLNZ04KFha-dOEStWqIAnZcufV2dkKiQIEZcqR2X6~cPYScDjy~mqaXEkrb4V3A9lZfq48LJ0Krav9g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"OC_0405_Registry_based_modelling_of_early_mortality_following_radiotherapy_of_lung_cancer","translated_slug":"","page_count":2,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186092,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186092/thumbnails/1.jpg","file_name":"s0167-814028192930825-420240205-1-54058o.pdf","download_url":"https://www.academia.edu/attachments/111186092/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"OC_0405_Registry_based_modelling_of_earl.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186092/s0167-814028192930825-420240205-1-54058o-libre.pdf?1707145122=\u0026response-content-disposition=attachment%3B+filename%3DOC_0405_Registry_based_modelling_of_earl.pdf\u0026Expires=1733027655\u0026Signature=UMAYxhPA3g86ud~YSu5HXSvlz3m~y9YZOICHmlYoB-sOD112Gr0JeaGw3R4ej8l0YL1dfmU0aPohEOmEP4rJMBWAqWnlP5z1Zn4qFz-M22ba937aOSobIKgN~SaWZlNzkCNc0r9TzfL3879lIBFAbKDlsBszJFwiI3xvPdhpqrmJoP~dqeT4iyywZcRX45IBVAdN8NN6S--P52mghVzeHjrsn69Mdg-IF0hXST7TCRgV80PeTHTgauuUQmqTlaW60yEqmlFvLNZ04KFha-dOEStWqIAnZcufV2dkKiQIEZcqR2X6~cPYScDjy~mqaXEkrb4V3A9lZfq48LJ0Krav9g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":3676351,"name":"Radiotherapy and Oncology","url":"https://www.academia.edu/Documents/in/Radiotherapy_and_Oncology"}],"urls":[{"id":39206123,"url":"https://doi.org/10.1016/s0167-8140(19)30825-4"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504836"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_"><img alt="Research paper thumbnail of Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_">Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504836"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504836"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504836; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504836]").text(description); $(".js-view-count[data-work-id=114504836]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504836; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504836']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504836, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=114504836]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504836,"title":"Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)","translated_title":"","metadata":{"abstract":"8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...","publisher":"American Society of Clinical Oncology (ASCO)","publication_name":"Journal of Clinical Oncology"},"translated_abstract":"8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID TRT of 45 Gy/30 fractions is the most recommended schedule. Trials report 5-year survival rates of up to 36%, illustrating that some are cured but also need for better treatment. Many treatment failures are due to relapses within TRT fields, and it has been proposed that higher TRT doses might improve local control and consequently survival. However, high-dose once-daily (QD) TRT of 66-70 Gy do not prolong survival. We investigated whether high-dose BID TRT of 60 Gy/40 fractions was tolerable and improved survival compared with the established 45 Gy schedule (NCT02041845). Primary analyses presented at ASCO 2020 showed that the trial was highly positive for the primary endpoint, 2-year survival (60 Gy: 74.2%, 45 Gy: 48.1%, OR 3.09 [95% CI 1.62-5.89]; p=0.0005). We now present updated and final survival data. Methods: Patients ≥18 years with PS 0-2, confirmed SCLC, LS according to the IASLC definit...","internal_url":"https://www.academia.edu/114504836/Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_","translated_internal_url":"","created_at":"2024-02-05T05:55:05.165-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Final_survival_data_from_a_randomized_phase_II_trial_comparing_high_dose_with_standard_dose_twice_daily_BID_thoracic_radiotherapy_TRT_in_limited_stage_small_cell_lung_cancer_LS_SCLC_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":10035,"name":"Nuclear medicine","url":"https://www.academia.edu/Documents/in/Nuclear_medicine"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":115895,"name":"Clinical oncology","url":"https://www.academia.edu/Documents/in/Clinical_oncology"},{"id":413196,"name":"Randomized Controlled Trial","url":"https://www.academia.edu/Documents/in/Randomized_Controlled_Trial"},{"id":2180163,"name":"Prophylactic Cranial Irradiation","url":"https://www.academia.edu/Documents/in/Prophylactic_Cranial_Irradiation"},{"id":2484597,"name":"Etoposide","url":"https://www.academia.edu/Documents/in/Etoposide"}],"urls":[{"id":39206122,"url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2023.41.16_suppl.8512"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504835"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy"><img alt="Research paper thumbnail of The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186102/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy">The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="777993275d9a560079b10d7c38cb1324" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186102,"asset_id":114504835,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504835"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504835"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504835; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504835]").text(description); $(".js-view-count[data-work-id=114504835]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504835; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504835']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504835, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "777993275d9a560079b10d7c38cb1324" } } $('.js-work-strip[data-work-id=114504835]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504835,"title":"The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":111186102},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504835/The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:04.915-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186102,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186102/thumbnails/1.jpg","file_name":"PIIS1556086421020748.pdf","download_url":"https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_HILUS_Trial_a_Prospective_Nordic_Mul.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186102/PIIS1556086421020748-libre.pdf?1707145127=\u0026response-content-disposition=attachment%3B+filename%3DThe_HILUS_Trial_a_Prospective_Nordic_Mul.pdf\u0026Expires=1733027655\u0026Signature=GfsCURbMxPLRjIpGlerQUOqVPtZXN8knzNHJb0WGg-J-J-oboPjVEl14NI1SZJB2olfR5DT1B7SW~LlRqlSmDpcwrNIU1n0c~JN9x54wq6Puh0iJmvPvwzDpVfn5A~iMC8CcH2YxOR1u98qIbikJzZb-IzwjjT4uNHX5XxA6rSeIusz7fSXXY0vveLzBvgrQcVs7joES3L1jIWQ-FihjfbJYDFL1-derDux~p0WqBjTOQqrNejnY2YZsamfvnXEctEcS6m4R4~U06sepId7AyzFvgfcowufDF~0vnfEczKRI6lSeZQ021axOX097Dd~pp5NUFcLyp4zACD0F22jlSQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_HILUS_Trial_a_Prospective_Nordic_Multicenter_Phase_2_Study_of_Ultracentral_Lung_Tumors_Treated_With_Stereotactic_Body_Radiotherapy","translated_slug":"","page_count":12,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186102,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186102/thumbnails/1.jpg","file_name":"PIIS1556086421020748.pdf","download_url":"https://www.academia.edu/attachments/111186102/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_HILUS_Trial_a_Prospective_Nordic_Mul.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186102/PIIS1556086421020748-libre.pdf?1707145127=\u0026response-content-disposition=attachment%3B+filename%3DThe_HILUS_Trial_a_Prospective_Nordic_Mul.pdf\u0026Expires=1733027655\u0026Signature=GfsCURbMxPLRjIpGlerQUOqVPtZXN8knzNHJb0WGg-J-J-oboPjVEl14NI1SZJB2olfR5DT1B7SW~LlRqlSmDpcwrNIU1n0c~JN9x54wq6Puh0iJmvPvwzDpVfn5A~iMC8CcH2YxOR1u98qIbikJzZb-IzwjjT4uNHX5XxA6rSeIusz7fSXXY0vveLzBvgrQcVs7joES3L1jIWQ-FihjfbJYDFL1-derDux~p0WqBjTOQqrNejnY2YZsamfvnXEctEcS6m4R4~U06sepId7AyzFvgfcowufDF~0vnfEczKRI6lSeZQ021axOX097Dd~pp5NUFcLyp4zACD0F22jlSQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":197297,"name":"Lung","url":"https://www.academia.edu/Documents/in/Lung"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":1281465,"name":"Univariate Analysis","url":"https://www.academia.edu/Documents/in/Univariate_Analysis"},{"id":2464960,"name":"Pneumonitis","url":"https://www.academia.edu/Documents/in/Pneumonitis"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":39206121,"url":"https://api.elsevier.com/content/article/PII:S1556086421020748?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504834"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy"><img alt="Research paper thumbnail of The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy" class="work-thumbnail" src="https://attachments.academia-assets.com/111186086/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy">The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy</a></div><div class="wp-workCard_item"><span>Neoplasma</span><span>, 2017</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bfcfc7d4d6dbc8cc12e1519c1303dddd" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186086,"asset_id":114504834,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504834"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504834"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504834; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504834]").text(description); $(".js-view-count[data-work-id=114504834]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504834; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504834']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504834, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bfcfc7d4d6dbc8cc12e1519c1303dddd" } } $('.js-work-strip[data-work-id=114504834]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504834,"title":"The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy","translated_title":"","metadata":{"publisher":"AEPress, s.r.o.","grobid_abstract":"Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical data and the serum values of hemoglobin (Hgb), White blood cells (WBC) and Platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox proportional hazards regression model. The results showed that patients with thrombocytosis (Plt \u003e 350 x 10 9 /L) had a shorter median overall survival (14.5 months) than patients with normal Plt at baseline (23.7 months). Patients with leukocytosis (WBC \u003e 9 x 10 9 /L) had a shorter median survival (14.9 months) than patients with a normal WBC at baseline (22.5 months). However, in a multivariate model including all lab parameters and clinical factors, only thrombocytosis and performance status displayed a prognostic significance. In Conclusion, thrombocytosis showed to be an independent prognostic marker associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. This knowledge can potentially be used together with established prognostic factors, such as performance status when choosing the optimal therapy for the individual patient in this clinical setting.","publication_date":{"day":null,"month":null,"year":2017,"errors":{}},"publication_name":"Neoplasma","grobid_abstract_attachment_id":111186086},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504834/The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy","translated_internal_url":"","created_at":"2024-02-05T05:55:04.700-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186086,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186086/thumbnails/1.jpg","file_name":"90383ee698ff3d04cc931a876a64742e6fbb.pdf","download_url":"https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_prognostic_value_of_pre_treatment_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186086/90383ee698ff3d04cc931a876a64742e6fbb-libre.pdf?1707145126=\u0026response-content-disposition=attachment%3B+filename%3DThe_prognostic_value_of_pre_treatment_th.pdf\u0026Expires=1733027655\u0026Signature=WNebByLbVLoulvj8GJlbEn82uutLqKUMuglhnzkx47q1kI8yiYKdcfNUWA6nEQ9TsQH4PA73twtZ7Nc54NQVOHgDEhpqDgZ2xNk1jHRZccmpHZItz2bHxY4vDsGbt3QocyGSHLbSV7WIeT7DE068KE9RM-pk9kjcFmCSdq-MOQka1fmixNsQRZi0TIqoNFUOcE4wqgGxyXzPC9EprMge0oq4-DVlNfNcEDRGTElV0JAWoica23fcm9OV~wOyUyX8Gkn4plS0kUJ6HbK28V3XUHNiZg7ayBtv4ybXMi7xedUrGm8jurddXjHTPl5qCxXQJvXb2FT7oMW-o0exxGh3pQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_prognostic_value_of_pre_treatment_thrombocytosis_in_two_cohorts_of_patients_with_non_small_cell_lung_cancer_treated_with_curatively_intended_chemoradiotherapy","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186086,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186086/thumbnails/1.jpg","file_name":"90383ee698ff3d04cc931a876a64742e6fbb.pdf","download_url":"https://www.academia.edu/attachments/111186086/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_prognostic_value_of_pre_treatment_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186086/90383ee698ff3d04cc931a876a64742e6fbb-libre.pdf?1707145126=\u0026response-content-disposition=attachment%3B+filename%3DThe_prognostic_value_of_pre_treatment_th.pdf\u0026Expires=1733027655\u0026Signature=WNebByLbVLoulvj8GJlbEn82uutLqKUMuglhnzkx47q1kI8yiYKdcfNUWA6nEQ9TsQH4PA73twtZ7Nc54NQVOHgDEhpqDgZ2xNk1jHRZccmpHZItz2bHxY4vDsGbt3QocyGSHLbSV7WIeT7DE068KE9RM-pk9kjcFmCSdq-MOQka1fmixNsQRZi0TIqoNFUOcE4wqgGxyXzPC9EprMge0oq4-DVlNfNcEDRGTElV0JAWoica23fcm9OV~wOyUyX8Gkn4plS0kUJ6HbK28V3XUHNiZg7ayBtv4ybXMi7xedUrGm8jurddXjHTPl5qCxXQJvXb2FT7oMW-o0exxGh3pQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":3274,"name":"Gastroenterology","url":"https://www.academia.edu/Documents/in/Gastroenterology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":418283,"name":"Proportional hazards model","url":"https://www.academia.edu/Documents/in/Proportional_hazards_model"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":1344434,"name":"Neoplasma","url":"https://www.academia.edu/Documents/in/Neoplasma"},{"id":3397707,"name":"Thrombocytosis","url":"https://www.academia.edu/Documents/in/Thrombocytosis"},{"id":3834133,"name":"leukocytosis","url":"https://www.academia.edu/Documents/in/leukocytosis"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504833"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study"><img alt="Research paper thumbnail of Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study" class="work-thumbnail" src="https://attachments.academia-assets.com/111186124/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study">Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study</a></div><div class="wp-workCard_item"><span>The Journal of Rheumatology</span><span>, 2013</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration &gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d0944487d04cb6f70a7896b46add6d2a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186124,"asset_id":114504833,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504833"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504833"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504833; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504833]").text(description); $(".js-view-count[data-work-id=114504833]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504833; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504833']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504833, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d0944487d04cb6f70a7896b46add6d2a" } } $('.js-work-strip[data-work-id=114504833]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504833,"title":"Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study","translated_title":"","metadata":{"abstract":"Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration \u0026gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...","publisher":"The Journal of Rheumatology","publication_date":{"day":null,"month":null,"year":2013,"errors":{}},"publication_name":"The Journal of Rheumatology"},"translated_abstract":"Objective.Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (PsA).Methods.In this 12-week RCT, patients with active disease (duration \u0026gt; 6 mo, ≥ 3 swollen and ≥ 3 tender joints) received apremilast (20 mg BID or 40 mg QD) or placebo. PRO included pain and global assessment of disease activity [visual analog scale (VAS)], Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Medical Outcomes Study Short-Form 36 Health Survey (SF-36) assessing health-related quality of life (HRQOL). Percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and correlations between SF-36 domains and pain VAS, HAQ-DI, and FACIT-F were determined.Results.Among the 204 randomize...","internal_url":"https://www.academia.edu/114504833/Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study","translated_internal_url":"","created_at":"2024-02-05T05:55:03.466-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186124,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186124/thumbnails/1.jpg","file_name":"1158.full.pdf","download_url":"https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Patient_reported_Health_related_Quality.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186124/1158.full-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPatient_reported_Health_related_Quality.pdf\u0026Expires=1733051180\u0026Signature=D~70v5nEi3qw6hwoJR7roPYN9LnZeeFJGISmKnB4Zpd7TXO24XS5BTeyw2M1J8BFypEYWT0LXommrZdZxLf3g27Kg9Aj4RoUby~Nyjn3bJT65jmX2BSvPugPiM0SLTNjD7FXdHGae3VVG2fsDAM21OFbOpxfSsFjYPLa9oSSrcD9RTD1YhGXrq5ec5KiFUqrNY0eWGIHSc2~Pl7ysup-6nH72tHXEAxTeXZkmJU8IwfouKdcmEXUQs83DqaCHg-OtI4oC-qIfOXYrgiW8bHbQoMPhERL3C3wfQxtrEuuY5fPEnpez5rx3OlUm7Off3YQS0rIrlR3mbGvdWMdTQQ68g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Patient_reported_Health_related_Quality_of_Life_with_Apremilast_for_Psoriatic_Arthritis_A_Phase_II_Randomized_Controlled_Study","translated_slug":"","page_count":8,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186124,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186124/thumbnails/1.jpg","file_name":"1158.full.pdf","download_url":"https://www.academia.edu/attachments/111186124/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Patient_reported_Health_related_Quality.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186124/1158.full-libre.pdf?1707145124=\u0026response-content-disposition=attachment%3B+filename%3DPatient_reported_Health_related_Quality.pdf\u0026Expires=1733051180\u0026Signature=D~70v5nEi3qw6hwoJR7roPYN9LnZeeFJGISmKnB4Zpd7TXO24XS5BTeyw2M1J8BFypEYWT0LXommrZdZxLf3g27Kg9Aj4RoUby~Nyjn3bJT65jmX2BSvPugPiM0SLTNjD7FXdHGae3VVG2fsDAM21OFbOpxfSsFjYPLa9oSSrcD9RTD1YhGXrq5ec5KiFUqrNY0eWGIHSc2~Pl7ysup-6nH72tHXEAxTeXZkmJU8IwfouKdcmEXUQs83DqaCHg-OtI4oC-qIfOXYrgiW8bHbQoMPhERL3C3wfQxtrEuuY5fPEnpez5rx3OlUm7Off3YQS0rIrlR3mbGvdWMdTQQ68g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1290,"name":"Immunology","url":"https://www.academia.edu/Documents/in/Immunology"},{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":23076,"name":"Fatigue","url":"https://www.academia.edu/Documents/in/Fatigue"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":32473,"name":"Physical Therapy","url":"https://www.academia.edu/Documents/in/Physical_Therapy"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":72938,"name":"Placebo","url":"https://www.academia.edu/Documents/in/Placebo"},{"id":144052,"name":"Patient Satisfaction","url":"https://www.academia.edu/Documents/in/Patient_Satisfaction"},{"id":205431,"name":"Psoriatic Arthritis","url":"https://www.academia.edu/Documents/in/Psoriatic_Arthritis"},{"id":232534,"name":"Health Status","url":"https://www.academia.edu/Documents/in/Health_Status"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":1262481,"name":"Pain Measurement","url":"https://www.academia.edu/Documents/in/Pain_Measurement"},{"id":2225268,"name":"Apremilast","url":"https://www.academia.edu/Documents/in/Apremilast"},{"id":2474752,"name":"Disability Evaluation","url":"https://www.academia.edu/Documents/in/Disability_Evaluation"}],"urls":[{"id":39206120,"url":"https://syndication.highwire.org/content/doi/10.3899/jrheum.121200"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="114504784"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer"><img alt="Research paper thumbnail of Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111186080/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer">Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer</a></div><div class="wp-workCard_item"><span>Medical Oncology</span><span>, May 8, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="eceee44affcbe1151c2cc3192ca3eec4" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111186080,"asset_id":114504784,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="114504784"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="114504784"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 114504784; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=114504784]").text(description); $(".js-view-count[data-work-id=114504784]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 114504784; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='114504784']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 114504784, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "eceee44affcbe1151c2cc3192ca3eec4" } } $('.js-work-strip[data-work-id=114504784]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":114504784,"title":"Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer","translated_title":"","metadata":{"publisher":"Springer Science+Business Media","grobid_abstract":"There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention ([50 Gy), were included in the study. WBC, Plt,","publication_date":{"day":8,"month":5,"year":2012,"errors":{}},"publication_name":"Medical Oncology","grobid_abstract_attachment_id":111186080},"translated_abstract":null,"internal_url":"https://www.academia.edu/114504784/Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer","translated_internal_url":"","created_at":"2024-02-05T05:53:14.172-08:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":111186080,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186080/thumbnails/1.jpg","file_name":"s12032-012-0247-320240205-1-alhlwl.pdf","download_url":"https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_lung_cancer_radiation_study_grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186080/s12032-012-0247-320240205-1-alhlwl-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_lung_cancer_radiation_study_grou.pdf\u0026Expires=1733027655\u0026Signature=GQK4sYvTIVJ19sCQgehsrSFFGsbJkeHSMs2KVjgBmM-9IGsz2IeAyOh86Um~Zx1lDugaLtxJDHuIGr2vrAixxn3ekd0ydZZei7Ng8TqNwoMXzmTkxIJXOaG8hs0UdlN2LWAylkqf16e01wR27lXVOiSxSsGCo0dPssivnGRhK-yizkEyAaQ~gw~i26MjJ3dUm4w7WEkdyCkIJhY8BST8SC56nqHn~o7VvGOmTpHgBHxyNoSBoBHpZTLoSMkfg1dIVCsbDA8t~0jZUjoGWKTRzT2SECP8mHRr45jYmaQmxagM0ERdChR4FOM1H6UKn5Ix87jdmHwZGFHWXPM2GZ22lw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Swedish_lung_cancer_radiation_study_group_the_prognostic_value_of_anaemia_thrombocytosis_and_leukocytosis_at_time_of_diagnosis_in_patients_with_non_small_cell_lung_cancer","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":111186080,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111186080/thumbnails/1.jpg","file_name":"s12032-012-0247-320240205-1-alhlwl.pdf","download_url":"https://www.academia.edu/attachments/111186080/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Swedish_lung_cancer_radiation_study_grou.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111186080/s12032-012-0247-320240205-1-alhlwl-libre.pdf?1707145121=\u0026response-content-disposition=attachment%3B+filename%3DSwedish_lung_cancer_radiation_study_grou.pdf\u0026Expires=1733027655\u0026Signature=GQK4sYvTIVJ19sCQgehsrSFFGsbJkeHSMs2KVjgBmM-9IGsz2IeAyOh86Um~Zx1lDugaLtxJDHuIGr2vrAixxn3ekd0ydZZei7Ng8TqNwoMXzmTkxIJXOaG8hs0UdlN2LWAylkqf16e01wR27lXVOiSxSsGCo0dPssivnGRhK-yizkEyAaQ~gw~i26MjJ3dUm4w7WEkdyCkIJhY8BST8SC56nqHn~o7VvGOmTpHgBHxyNoSBoBHpZTLoSMkfg1dIVCsbDA8t~0jZUjoGWKTRzT2SECP8mHRr45jYmaQmxagM0ERdChR4FOM1H6UKn5Ix87jdmHwZGFHWXPM2GZ22lw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":619,"name":"Hematology","url":"https://www.academia.edu/Documents/in/Hematology"},{"id":3274,"name":"Gastroenterology","url":"https://www.academia.edu/Documents/in/Gastroenterology"},{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":64900,"name":"Medical Oncology","url":"https://www.academia.edu/Documents/in/Medical_Oncology"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":136346,"name":"Anemia","url":"https://www.academia.edu/Documents/in/Anemia"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":338534,"name":"Biomarker","url":"https://www.academia.edu/Documents/in/Biomarker"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"},{"id":3118074,"name":"Neoplasm staging","url":"https://www.academia.edu/Documents/in/Neoplasm_staging"},{"id":3834133,"name":"leukocytosis","url":"https://www.academia.edu/Documents/in/leukocytosis"},{"id":3840853,"name":"lung neoplasms","url":"https://www.academia.edu/Documents/in/lung_neoplasms"}],"urls":[{"id":39206096,"url":"https://doi.org/10.1007/s12032-012-0247-3"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="108018969"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial"><img alt="Research paper thumbnail of MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial" class="work-thumbnail" src="https://attachments.academia-assets.com/106517408/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial">MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial</a></div><div class="wp-workCard_item"><span>Journal of Thoracic Oncology</span><span>, Oct 1, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d7178e2a1642324e9664d40e194eea4b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":106517408,"asset_id":108018969,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="108018969"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="108018969"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 108018969; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=108018969]").text(description); $(".js-view-count[data-work-id=108018969]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 108018969; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='108018969']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 108018969, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d7178e2a1642324e9664d40e194eea4b" } } $('.js-work-strip[data-work-id=108018969]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":108018969,"title":"MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial","translated_title":"","metadata":{"publisher":"Elsevier BV","grobid_abstract":"11.8Gy (1.0-20.4Gy), and lung V20 from 23.7% (1.5-47.8%) to 20.8% (1.2-39.7%). Reduced lung dose translated to reduced pneumonitis risk: from 8.6% (2.3-23.3%) to 6.5% (2.2-14.4%). Lung dose constraints were violated in 5/62 patients in FB and 1/62 patients in DIBH. Mean heart dose was reduced from 3.6Gy (0.1-25.8Gy) in FB to 2.4Gy (0.1-25.3Gy) in DIBH. DIBH reduced mean heart dose in 44/61 patients. The differences between FB and DIBH varied between e 6.6Gy and 8.9Gy, stressing the influence of tumour location on the potential of reducing heart dose with DIBH. Conclusion: Benefits of changed anatomy with DIBH were reduced dose to lungs and, for most patients, to the heart. Curative treatment intent could be maintained in more patients. Risk of developing radiation pneumonitis was reduced. Continuous follow up of INHALE patients will reveal how the reduced risk is manifested clinically.","publication_date":{"day":1,"month":10,"year":2018,"errors":{}},"publication_name":"Journal of Thoracic Oncology","grobid_abstract_attachment_id":106517408},"translated_abstract":null,"internal_url":"https://www.academia.edu/108018969/MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial","translated_internal_url":"","created_at":"2023-10-11T22:58:41.071-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":106517408,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517408/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517408/pdf-libre.pdf?1697091026=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=gzgFUO-r1eBpQjoGYpGsRAFS2pDqt2-9Oir3xptRi6gavFG2CJknGtnW097qu-ddr06V6CbDB8UrNW8QtQg66xdsbkA~NJabG62fyTUqKbYGjLwXYBSIHbJHNH7JV1lUIc37xD8gXr~tZjjkfRKAN13WcxXKS7Ez~-DXewkvBR8UOIHrEbh3m4mOQvcNA1TXYgyOzIKSfKU-GhiufmEfP0Z-ri-9AyA3cgzK~YzlrW-OVh6nwbDQm~HY4u7ZaVceZDyshXa4uOAvBzIKQSCSs~dLYPCEzyAI6aob~slFAyYenE38EfFp8gHrwjpL9BQAseMuknOOAYq21bk1GjNSoQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy_in_Stage_III_NSCLC_Appears_Excessively_Toxic_Results_from_a_Randomized_Phase_II_Trial","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":106517408,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517408/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517408/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517408/pdf-libre.pdf?1697091026=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=gzgFUO-r1eBpQjoGYpGsRAFS2pDqt2-9Oir3xptRi6gavFG2CJknGtnW097qu-ddr06V6CbDB8UrNW8QtQg66xdsbkA~NJabG62fyTUqKbYGjLwXYBSIHbJHNH7JV1lUIc37xD8gXr~tZjjkfRKAN13WcxXKS7Ez~-DXewkvBR8UOIHrEbh3m4mOQvcNA1TXYgyOzIKSfKU-GhiufmEfP0Z-ri-9AyA3cgzK~YzlrW-OVh6nwbDQm~HY4u7ZaVceZDyshXa4uOAvBzIKQSCSs~dLYPCEzyAI6aob~slFAyYenE38EfFp8gHrwjpL9BQAseMuknOOAYq21bk1GjNSoQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":106517409,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517409/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/106517409/download_file","bulk_download_file_name":"MA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517409/pdf-libre.pdf?1697091024=\u0026response-content-disposition=attachment%3B+filename%3DMA05_07_Dose_Escalated_Chemo_RT_to_84_Gy.pdf\u0026Expires=1733027655\u0026Signature=Epdih2qBYqv5mAZ2kg3tc8U9eyLGKHOubFPZsiT2dEondiBFIm46tM8qaw5BQtX~djYGzpghN5vDty9IV4HelmoKclcd2vLQt3Qu5EQu17Fjhw4nvHGKVKe13pXg~hl3FgCtuU3b54qP1woH2u1i6qrGpnQ1Of~An7UaJeR1wy6p78N-ZYi3KCScDu2W3qwN02Xd9DQhVSrCJMTIsUq80NHyrTyfDNvI0uIn3Q8NiFqpDoMjZQ7F4AsVFdUJpUeYuz1uJb5LdP8gYnPP3xKxQGXZ-DIwa~mUf7rkG9cXZdJkW3yzYw2DaqMoGcv6qM4MIoC~jETKeJB3nZwNpRyk4A__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":574442,"name":"Thoracic Oncology","url":"https://www.academia.edu/Documents/in/Thoracic_Oncology"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":34621209,"url":"http://www.jto.org/article/S1556086418313121/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="108018966"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial"><img alt="Research paper thumbnail of High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial" class="work-thumbnail" src="https://attachments.academia-assets.com/106517433/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial">High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial</a></div><div class="wp-workCard_item"><span>The Lancet Oncology</span><span>, 2021</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="24faed3226b56309c6e652195fdf1987" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":106517433,"asset_id":108018966,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="108018966"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="108018966"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 108018966; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=108018966]").text(description); $(".js-view-count[data-work-id=108018966]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 108018966; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='108018966']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 108018966, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "24faed3226b56309c6e652195fdf1987" } } $('.js-work-strip[data-work-id=108018966]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":108018966,"title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"The Lancet Oncology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/108018966/High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial","translated_internal_url":"","created_at":"2023-10-11T22:58:40.429-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":39973590,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":106517433,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517433/thumbnails/1.jpg","file_name":"High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_.pdf","download_url":"https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"High_dose_versus_standard_dose_twice_dai.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517433/High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_-libre.pdf?1697091033=\u0026response-content-disposition=attachment%3B+filename%3DHigh_dose_versus_standard_dose_twice_dai.pdf\u0026Expires=1733051180\u0026Signature=I6UmcJl~JLubhf4lVj-hK-cirTqCNsZL1MkheHaNGELrcRd9xgawe9~GRW~~qv3RS-cnVHKXatSlZzYgtlXAXTQ3wMlcBb3IKtivL7kSdFVZB~349J6BfG3IxHYT3-xdJ0ND5h2b5BRgsWh6M4-crhU0jRLyOdkd30t2mr496LNh~GqvBOeE2xc~svO9DRat8wENxdtvG8FUChqjHVjehonL3WjP90G31gbU47zmwRbs0KKHbMUN0ZUQ6db25XOPAYyOknURmGlD-TglSZGL~KjascqLi4BZwAa6JSMDkIZdqPSwD2LNDgfBaLJHouha157e5zJfSx9WbzoC~ItwJw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"High_dose_versus_standard_dose_twice_daily_thoracic_radiotherapy_for_patients_with_limited_stage_small_cell_lung_cancer_an_open_label_randomised_phase_2_trial","translated_slug":"","page_count":16,"language":"en","content_type":"Work","owner":{"id":39973590,"first_name":"Jan","middle_initials":null,"last_name":"Nyman","page_name":"JanNyman","domain_name":"independent","created_at":"2015-12-10T02:53:17.299-08:00","display_name":"Jan Nyman","url":"https://independent.academia.edu/JanNyman"},"attachments":[{"id":106517433,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/106517433/thumbnails/1.jpg","file_name":"High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_.pdf","download_url":"https://www.academia.edu/attachments/106517433/download_file?st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&st=MTczMzA0NzU4MCw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"High_dose_versus_standard_dose_twice_dai.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/106517433/High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_-libre.pdf?1697091033=\u0026response-content-disposition=attachment%3B+filename%3DHigh_dose_versus_standard_dose_twice_dai.pdf\u0026Expires=1733051180\u0026Signature=I6UmcJl~JLubhf4lVj-hK-cirTqCNsZL1MkheHaNGELrcRd9xgawe9~GRW~~qv3RS-cnVHKXatSlZzYgtlXAXTQ3wMlcBb3IKtivL7kSdFVZB~349J6BfG3IxHYT3-xdJ0ND5h2b5BRgsWh6M4-crhU0jRLyOdkd30t2mr496LNh~GqvBOeE2xc~svO9DRat8wENxdtvG8FUChqjHVjehonL3WjP90G31gbU47zmwRbs0KKHbMUN0ZUQ6db25XOPAYyOknURmGlD-TglSZGL~KjascqLi4BZwAa6JSMDkIZdqPSwD2LNDgfBaLJHouha157e5zJfSx9WbzoC~ItwJw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10030,"name":"Radiation Therapy","url":"https://www.academia.edu/Documents/in/Radiation_Therapy"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":51698,"name":"Lung Cancer","url":"https://www.academia.edu/Documents/in/Lung_Cancer"},{"id":243630,"name":"Lancet Oncology","url":"https://www.academia.edu/Documents/in/Lancet_Oncology"},{"id":884014,"name":"Chemoradiotherapy","url":"https://www.academia.edu/Documents/in/Chemoradiotherapy"},{"id":2007840,"name":"Carboplatin","url":"https://www.academia.edu/Documents/in/Carboplatin"},{"id":2180163,"name":"Prophylactic Cranial Irradiation","url":"https://www.academia.edu/Documents/in/Prophylactic_Cranial_Irradiation"}],"urls":[{"id":34621207,"url":"https://api.elsevier.com/content/article/PII:S1470204520307427?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/google_contacts-0dfb882d836b94dbcb4a2d123d6933fc9533eda5be911641f20b4eb428429600.js"], function() { // from javascript_helper.rb $('.js-google-connect-button').click(function(e) { e.preventDefault(); GoogleContacts.authorize_and_show_contacts(); Aedu.Dismissibles.recordClickthrough("WowProfileImportContactsPrompt"); }); $('.js-update-biography-button').click(function(e) { e.preventDefault(); Aedu.Dismissibles.recordClickthrough("UpdateUserBiographyPrompt"); $.ajax({ url: $r.api_v0_profiles_update_about_path({ subdomain_param: 'api', about: "", }), type: 'PUT', success: function(response) { location.reload(); } }); }); $('.js-work-creator-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_document_path({ source: encodeURIComponent(""), }); }); $('.js-video-upload-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_video_path({ source: encodeURIComponent(""), }); }); $('.js-do-this-later-button').click(function() { $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("WowProfileImportContactsPrompt"); }); $('.js-update-biography-do-this-later-button').click(function(){ $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("UpdateUserBiographyPrompt"); }); $('.wow-profile-mentions-upsell--close').click(function(){ $('.wow-profile-mentions-upsell--panel').hide(); Aedu.Dismissibles.recordDismissal("WowProfileMentionsUpsell"); }); $('.wow-profile-mentions-upsell--button').click(function(){ Aedu.Dismissibles.recordClickthrough("WowProfileMentionsUpsell"); }); new WowProfile.SocialRedesignUserWorks({ initialWorksOffset: 20, allWorksOffset: 20, maxSections: 1 }) }); </script> </div></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile_edit-5ea339ee107c863779f560dd7275595239fed73f1a13d279d2b599a28c0ecd33.js","https://a.academia-assets.com/assets/add_coauthor-22174b608f9cb871d03443cafa7feac496fb50d7df2d66a53f5ee3c04ba67f53.js","https://a.academia-assets.com/assets/tab-dcac0130902f0cc2d8cb403714dd47454f11fc6fb0e99ae6a0827b06613abc20.js","https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js"], function() { // from javascript_helper.rb window.ae = window.ae || {}; window.ae.WowProfile = window.ae.WowProfile || {}; if(Aedu.User.current && Aedu.User.current.id === $viewedUser.id) { window.ae.WowProfile.current_user_edit = {}; new WowProfileEdit.EditUploadView({ el: '.js-edit-upload-button-wrapper', model: window.$current_user, }); new AddCoauthor.AddCoauthorsController(); } var userInfoView = new WowProfile.SocialRedesignUserInfo({ recaptcha_key: "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB" }); WowProfile.router = new WowProfile.Router({ userInfoView: userInfoView }); Backbone.history.start({ pushState: true, root: "/" + $viewedUser.page_name }); new WowProfile.UserWorksNav() }); </script> </div> <div class="bootstrap login"><div class="modal fade login-modal" id="login-modal"><div class="login-modal-dialog modal-dialog"><div class="modal-content"><div class="modal-header"><button class="close close" data-dismiss="modal" type="button"><span aria-hidden="true">×</span><span class="sr-only">Close</span></button><h4 class="modal-title text-center"><strong>Log In</strong></h4></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><button class="btn btn-fb btn-lg btn-block btn-v-center-content" id="login-facebook-oauth-button"><svg style="float: left; width: 19px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook-square" class="svg-inline--fa fa-facebook-square fa-w-14" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg><small><strong>Log in</strong> with <strong>Facebook</strong></small></button><br /><button class="btn btn-google btn-lg btn-block btn-v-center-content" id="login-google-oauth-button"><svg style="float: left; width: 22px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="google-plus" class="svg-inline--fa fa-google-plus fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M256,8C119.1,8,8,119.1,8,256S119.1,504,256,504,504,392.9,504,256,392.9,8,256,8ZM185.3,380a124,124,0,0,1,0-248c31.3,0,60.1,11,83,32.3l-33.6,32.6c-13.2-12.9-31.3-19.1-49.4-19.1-42.9,0-77.2,35.5-77.2,78.1S142.3,334,185.3,334c32.6,0,64.9-19.1,70.1-53.3H185.3V238.1H302.2a109.2,109.2,0,0,1,1.9,20.7c0,70.8-47.5,121.2-118.8,121.2ZM415.5,273.8v35.5H380V273.8H344.5V238.3H380V202.8h35.5v35.5h35.2v35.5Z"></path></svg><small><strong>Log in</strong> with <strong>Google</strong></small></button><br /><style type="text/css">.sign-in-with-apple-button { width: 100%; height: 52px; border-radius: 3px; border: 1px solid black; cursor: pointer; }</style><script src="https://appleid.cdn-apple.com/appleauth/static/jsapi/appleid/1/en_US/appleid.auth.js" type="text/javascript"></script><div class="sign-in-with-apple-button" data-border="false" data-color="white" id="appleid-signin"><span   ="Sign Up with Apple" class="u-fs11"></span></div><script>AppleID.auth.init({ clientId: 'edu.academia.applesignon', scope: 'name email', redirectURI: 'https://www.academia.edu/sessions', state: "5a1003555ef41b13319fd2dba114baef8d63252bbd8d076575f496ca95c04b36", });</script><script>// Hacky way of checking if on fast loswp if (window.loswp == null) { (function() { const Google = window?.Aedu?.Auth?.OauthButton?.Login?.Google; const Facebook = window?.Aedu?.Auth?.OauthButton?.Login?.Facebook; if (Google) { new Google({ el: '#login-google-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } if (Facebook) { new Facebook({ el: '#login-facebook-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } })(); }</script></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><div class="hr-heading login-hr-heading"><span class="hr-heading-text">or</span></div></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><form class="js-login-form" action="https://www.academia.edu/sessions" accept-charset="UTF-8" method="post"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><input type="hidden" name="authenticity_token" value="LgB4K1KXEMOzxG/g2eWGzevRkRPSNbVgYIDJEB1TPhw9x2wEQLmNLkfYRXp2rKmSCo6xRYDVd/7HbwpSEHyINg==" autocomplete="off" /><div class="form-group"><label class="control-label" for="login-modal-email-input" style="font-size: 14px;">Email</label><input class="form-control" id="login-modal-email-input" name="login" type="email" /></div><div class="form-group"><label class="control-label" for="login-modal-password-input" style="font-size: 14px;">Password</label><input class="form-control" id="login-modal-password-input" name="password" type="password" /></div><input type="hidden" name="post_login_redirect_url" id="post_login_redirect_url" value="https://independent.academia.edu/JanNyman" autocomplete="off" /><div class="checkbox"><label><input type="checkbox" name="remember_me" id="remember_me" value="1" checked="checked" /><small style="font-size: 12px; margin-top: 2px; display: inline-block;">Remember me on this computer</small></label></div><br><input type="submit" name="commit" value="Log In" class="btn btn-primary btn-block btn-lg js-login-submit" data-disable-with="Log In" /></br></form><script>typeof window?.Aedu?.recaptchaManagedForm === 'function' && window.Aedu.recaptchaManagedForm( document.querySelector('.js-login-form'), document.querySelector('.js-login-submit') );</script><small style="font-size: 12px;"><br />or <a data-target="#login-modal-reset-password-container" data-toggle="collapse" href="javascript:void(0)">reset password</a></small><div class="collapse" id="login-modal-reset-password-container"><br /><div class="well margin-0x"><form class="js-password-reset-form" action="https://www.academia.edu/reset_password" accept-charset="UTF-8" method="post"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><input type="hidden" name="authenticity_token" value="ZwVAg1h8s7lKGB1RxrYcdZdD/IGVcfH50jdj2Jiv9mB0wlSsSlIuVL4EN8tp/zMqdhzc18eRM2d12KCalYBASg==" autocomplete="off" /><p>Enter the email address you signed up with and we'll email you a reset link.</p><div class="form-group"><input class="form-control" name="email" type="email" /></div><script src="https://recaptcha.net/recaptcha/api.js" async defer></script> <script> var invisibleRecaptchaSubmit = function () { var closestForm = function (ele) { var curEle = ele.parentNode; while (curEle.nodeName !== 'FORM' && curEle.nodeName !== 'BODY'){ curEle = curEle.parentNode; } return curEle.nodeName === 'FORM' ? curEle : null }; var eles = document.getElementsByClassName('g-recaptcha'); if (eles.length > 0) { var form = closestForm(eles[0]); if (form) { form.submit(); } } }; </script> <input type="submit" data-sitekey="6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj" data-callback="invisibleRecaptchaSubmit" class="g-recaptcha btn btn-primary btn-block" value="Email me a link" value=""/> </form></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/collapse-45805421cf446ca5adf7aaa1935b08a3a8d1d9a6cc5d91a62a2a3a00b20b3e6a.js"], function() { // from javascript_helper.rb $("#login-modal-reset-password-container").on("shown.bs.collapse", function() { $(this).find("input[type=email]").focus(); }); }); </script> </div></div></div><div class="modal-footer"><div class="text-center"><small style="font-size: 12px;">Need an account? <a rel="nofollow" href="https://www.academia.edu/signup">Click here to sign up</a></small></div></div></div></div></div></div><script>// If we are on subdomain or non-bootstrapped page, redirect to login page instead of showing modal (function(){ if (typeof $ === 'undefined') return; var host = window.location.hostname; if ((host === $domain || host === "www."+$domain) && (typeof $().modal === 'function')) { $("#nav_log_in").click(function(e) { // Don't follow the link and open the modal e.preventDefault(); $("#login-modal").on('shown.bs.modal', function() { $(this).find("#login-modal-email-input").focus() }).modal('show'); }); } })()</script> <div class="bootstrap" id="footer"><div class="footer-content clearfix text-center padding-top-7x" style="width:100%;"><ul class="footer-links-secondary footer-links-wide list-inline margin-bottom-1x"><li><a href="https://www.academia.edu/about">About</a></li><li><a href="https://www.academia.edu/press">Press</a></li><li><a rel="nofollow" href="https://medium.com/academia">Blog</a></li><li><a href="https://www.academia.edu/documents">Papers</a></li><li><a href="https://www.academia.edu/topics">Topics</a></li><li><a href="https://www.academia.edu/journals">Academia.edu Journals</a></li><li><a rel="nofollow" href="https://www.academia.edu/hiring"><svg style="width: 13px; height: 13px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="briefcase" class="svg-inline--fa fa-briefcase fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M320 336c0 8.84-7.16 16-16 16h-96c-8.84 0-16-7.16-16-16v-48H0v144c0 25.6 22.4 48 48 48h416c25.6 0 48-22.4 48-48V288H320v48zm144-208h-80V80c0-25.6-22.4-48-48-48H176c-25.6 0-48 22.4-48 48v48H48c-25.6 0-48 22.4-48 48v80h512v-80c0-25.6-22.4-48-48-48zm-144 0H192V96h128v32z"></path></svg> <strong>We're Hiring!</strong></a></li><li><a rel="nofollow" href="https://support.academia.edu/"><svg style="width: 12px; height: 12px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="question-circle" class="svg-inline--fa fa-question-circle fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M504 256c0 136.997-111.043 248-248 248S8 392.997 8 256C8 119.083 119.043 8 256 8s248 111.083 248 248zM262.655 90c-54.497 0-89.255 22.957-116.549 63.758-3.536 5.286-2.353 12.415 2.715 16.258l34.699 26.31c5.205 3.947 12.621 3.008 16.665-2.122 17.864-22.658 30.113-35.797 57.303-35.797 20.429 0 45.698 13.148 45.698 32.958 0 14.976-12.363 22.667-32.534 33.976C247.128 238.528 216 254.941 216 296v4c0 6.627 5.373 12 12 12h56c6.627 0 12-5.373 12-12v-1.333c0-28.462 83.186-29.647 83.186-106.667 0-58.002-60.165-102-116.531-102zM256 338c-25.365 0-46 20.635-46 46 0 25.364 20.635 46 46 46s46-20.636 46-46c0-25.365-20.635-46-46-46z"></path></svg> <strong>Help Center</strong></a></li></ul><ul class="footer-links-tertiary list-inline margin-bottom-1x"><li class="small">Find new research papers in:</li><li class="small"><a href="https://www.academia.edu/Documents/in/Physics">Physics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Chemistry">Chemistry</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Biology">Biology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Health_Sciences">Health Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Ecology">Ecology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Earth_Sciences">Earth Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Cognitive_Science">Cognitive Science</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Mathematics">Mathematics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Computer_Science">Computer Science</a></li></ul></div></div><div class="DesignSystem" id="credit" style="width:100%;"><ul class="u-pl0x footer-links-legal list-inline"><li><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li>Academia ©2024</li></ul></div><script> //<![CDATA[ window.detect_gmtoffset = true; window.Academia && window.Academia.set_gmtoffset && Academia.set_gmtoffset('/gmtoffset'); //]]> </script> <div id='overlay_background'></div> <div id='bootstrap-modal-container' class='bootstrap'></div> <div id='ds-modal-container' class='bootstrap DesignSystem'></div> <div id='full-screen-modal'></div> </div> </body> </html>